

Philippe Gabriel Steg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/907441/publications.pdf>

Version: 2024-02-01

918
papers

151,524
citations

196

149
h-index

77

370
g-index

935
all docs

935
docs citations

935
times ranked

68728
citing authors

#	ARTICLE	IF	CITATIONS
1	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	1.0	7,100
2	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 361, 1045-1057.	13.9	6,019
3	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	1.0	5,034
4	Clinical End Points in Coronary Stent Trials. <i>Circulation</i> , 2007, 115, 2344-2351.	1.6	4,993
5	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	1.0	3,915
6	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. <i>Circulation</i> , 2011, 123, 2736-2747.	1.6	3,378
7	Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure. <i>New England Journal of Medicine</i> , 2002, 347, 161-167.	13.9	3,057
8	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2013, 369, 1317-1326.	13.9	3,017
9	Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2007, 116, 2634-2653.	1.6	2,755
10	Third Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2012, 126, 2020-2035.	1.6	2,722
11	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	1.0	2,687
12	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. <i>New England Journal of Medicine</i> , 2006, 354, 1706-1717.	13.9	2,582
13	Third Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1581-1598.	1.2	2,558
14	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 2551-2567.	1.0	2,447
15	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
16	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	1.0	2,246
17	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	13.9	2,211
18	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2019, 380, 11-22.	13.9	2,153

#	ARTICLE	IF	CITATIONS
19	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. <i>European Heart Journal</i> , 2008, 29, 2909-2945.	1.0	2,128
20	Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. <i>Lancet</i> , The, 2011, 377, 1409-1420.	6.3	1,759
21	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
22	Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. <i>New England Journal of Medicine</i> , 2014, 371, 2155-2166.	13.9	1,645
23	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015, 372, 1791-1800.	13.9	1,585
24	Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2009, 360, 363-375.	13.9	1,581
25	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1395-1407.	13.9	1,508
26	International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 180.	3.8	1,353
27	A Validated Prediction Model for All Forms of Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2727.	3.8	1,344
28	One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1197.	3.8	1,162
29	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017, 377, 1513-1524.	13.9	1,099
30	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 117-128.	13.9	1,080
31	Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1821.	3.8	980
32	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2008, 372, 807-816.	6.3	934
33	Resting Heart Rate in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2007, 50, 823-830.	1.2	867
34	Elevated Levels of Shed Membrane Microparticles With Procoagulant Potential in the Peripheral Circulating Blood of Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2000, 101, 841-843.	1.6	851
35	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. <i>Lancet</i> , The, 2017, 389, 1025-1034.	6.3	840
36	B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure. <i>Circulation</i> , 2002, 106, 416-422.	1.6	811

#	ARTICLE	IF	CITATIONS
37	Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1735.	3.8	759
38	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1982-1988.	1.2	752
39	Early versus Delayed Invasive Intervention in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 360, 2165-2175.	13.9	748
40	Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1892.	3.8	744
41	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , 2010, 376, 1233-1243.	6.3	725
42	A Cause for Concern. <i>Circulation</i> , 2007, 115, 1440-1455.	1.6	724
43	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. <i>Lancet, The</i> , 2010, 376, 1320-1328.	6.3	709
44	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. <i>New England Journal of Medicine</i> , 2013, 368, 1303-1313.	13.9	695
45	Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. <i>Lancet, The</i> , 2008, 372, 817-821.	6.3	694
46	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.	13.9	683
47	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021, 384, 129-139.	13.9	662
48	Coronary Intervention for Persistent Occlusion after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2006, 355, 2395-2407.	13.9	635
49	Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1350.	3.8	626
50	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. <i>Lancet, The</i> , 2010, 375, 283-293.	6.3	624
51	A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. <i>Lancet Neurology, The</i> , 2007, 6, 953-960.	4.9	602
52	Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. <i>Circulation</i> , 2014, 130, 1579-1588.	1.6	594
53	Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. <i>European Heart Journal</i> , 2012, 33, 2831-2840.	1.0	560
54	Cyclosporine before PCI in Patients with Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015, 373, 1021-1031.	13.9	557

#	ARTICLE	IF	CITATIONS
55	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> , 2018, 392, 940-949.	6.3	555
56	Complete Revascularization with Multivessel PCI for Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 381, 1411-1421.	13.9	542
57	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet, The</i> , 2013, 382, 1714-1722.	6.3	537
58	Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. <i>New England Journal of Medicine</i> , 2015, 372, 1389-1398.	13.9	536
59	Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)**Further information about the project, along with a complete list of the study participants, can be found at www.outcomes.org/grace .. <i>American Journal of Cardiology</i> , 2002, 90, 358-363.	0.7	534
60	Impact of Time to Treatment on Mortality After Prehospital Fibrinolysis or Primary Angioplasty. <i>Circulation</i> , 2003, 108, 2851-2856.	1.6	509
61	A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2006, 48, 931-938.	1.2	509
62	Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2010, 122, 2131-2141.	1.6	474
63	Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). <i>European Heart Journal</i> , 2002, 23, 1177-1189.	1.0	467
64	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1702-1711.	13.9	467
65	B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the breathing not properly multinational study. <i>American Journal of Kidney Diseases</i> , 2003, 41, 571-579.	2.1	464
66	Determinants and Prognostic Impact of Heart Failure Complicating Acute Coronary Syndromes. <i>Circulation</i> , 2004, 109, 494-499.	1.6	462
67	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2224-2234.	1.2	445
68	One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. <i>New England Journal of Medicine</i> , 2016, 374, 1533-1542.	13.9	444
69	Bivalirudin Started during Emergency Transport for Primary PCI. <i>New England Journal of Medicine</i> , 2013, 369, 2207-2217.	13.9	443
70	Acute Coronary Syndromes Without Chest Pain, An Underdiagnosed and Undertreated High-Risk Group. <i>Chest</i> , 2004, 126, 461-469.	0.4	439
71	Association of Changes in Clinical Characteristics and Management With Improvement in Survival Among Patients With ST-Elevation Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 998.	3.8	402
72	Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure. <i>New England Journal of Medicine</i> , 2014, 371, 1091-1099.	13.9	399

#	ARTICLE	IF	CITATIONS
73	Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death. <i>Circulation</i> , 2015, 132, 923-931.	1.6	397
74	Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1006.	3.8	375
75	Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. <i>Lancet, The</i> , 2008, 371, 559-568.	6.3	371
76	Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 43.	3.8	368
77	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. <i>American Heart Journal</i> , 2014, 168, 682-689.e1.	1.2	365
78	Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2009, 157, 599-605.	1.2	363
79	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. <i>Lancet, The</i> , 2016, 388, 2142-2152.	6.3	357
80	Acute Myocardial Infarction. <i>Circulation</i> , 2017, 136, 1908-1919.	1.6	352
81	Effects of Radial Versus Femoral Artery Access in Patients With Acute Coronary Syndromes With or Without ST-Segment Elevation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2490-2499.	1.2	349
82	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1854-1864.	1.0	343
83	A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. <i>New England Journal of Medicine</i> , 2020, 382, 9-19.	13.9	339
84	Enoxaparin versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention. <i>New England Journal of Medicine</i> , 2006, 355, 1006-1017.	13.9	325
85	Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis<alt-title>Metformin Use With Diabetes and Atherothrombosis</alt-title>. <i>Archives of Internal Medicine</i> , 2010, 170, 1892.	4.3	319
86	Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2141-2147.	1.2	308
87	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2719-2728.	1.2	303
88	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	1.2	296
89	Patients with peripheral arterial disease in the CHARISMA trial. <i>European Heart Journal</i> , 2008, 30, 192-201.	1.0	290
90	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. <i>Lancet, The</i> , 2013, 382, 1981-1992.	6.3	286

#	ARTICLE	IF	CITATIONS
91	Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. <i>European Heart Journal</i> , 2011, 32, 2143-2152.	1.0	285
92	Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. <i>European Heart Journal</i> , 2009, 30, 2318-2326.	1.0	277
93	Comparison of Thrombolysis Followed by Broad Use of Percutaneous Coronary Intervention With Primary Percutaneous Coronary Intervention for ST-Segmentâ€Elevation Acute Myocardial Infarction. <i>Circulation</i> , 2008, 118, 268-276.	1.6	275
94	Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. <i>BMJ Open</i> , 2014, 4, e004425.	0.8	273
95	Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). <i>American Journal of Cardiology</i> , 2002, 89, 791-796.	0.7	271
96	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78.	0.6	261
97	Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 632-639.	2.1	259
98	Immediate vs Delayed Intervention for Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 947.	3.8	255
99	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 1309-1320.	13.9	255
100	External Validity of Clinical Trials in Acute Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2007, 167, 68.	4.3	250
101	Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. <i>BMJ: British Medical Journal</i> , 2011, 342, d3527-d3527.	2.4	246
102	Implications of Diabetes in Patients With Acute Coronary Syndromes<subtitle>The Global Registry of Acute Coronary Events</subtitle>. <i>Archives of Internal Medicine</i> , 2004, 164, 1457.	4.3	244
103	Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. <i>American Heart Journal</i> , 2008, 156, 855-863.e2.	1.2	243
104	Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2211-2221.	1.2	240
105	How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. <i>American Heart Journal</i> , 2006, 151, 999-1005.	1.2	238
106	Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. <i>European Heart Journal</i> , 2014, 35, 2864-2872.	1.0	238
107	Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. <i>New England Journal of Medicine</i> , 2018, 378, 2182-2190.	13.9	238
108	The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. <i>American Heart Journal</i> , 2006, 151, 786.e1-786.e10.	1.2	235

#	ARTICLE	IF	CITATIONS
109	Gender Differences in Hospital Mortality and Use of Percutaneous Coronary Intervention in Acute Myocardial Infarction. <i>Circulation</i> , 2007, 115, 833-839.	1.6	234
110	Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. <i>European Heart Journal</i> , 2008, 29, 609-617.	1.0	233
111	Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 191-197.	1.1	229
112	Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. <i>Lancet</i> , The, 2010, 376, 517-523.	6.3	222
113	Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Atherosclerosis</i> , 2009, 204, e86-e92.	0.4	220
114	Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease. <i>Circulation</i> , 2010, 121, 2575-2583.	1.6	218
115	Dual Antiplatelet Therapy Duration Based On Ischemic and Bleeding Risks After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 73, 741-754.	1.2	218
116	Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction?. <i>Circulation</i> , 2007, 116, 2793-2801.	1.6	213
117	Differentiating Acute Myocardial Infarction from Myocarditis: Diagnostic Value of Early- and Delayed-Perfusion Cardiac MR Imaging. <i>Radiology</i> , 2005, 237, 75-82.	3.6	211
118	Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid. <i>Circulation</i> , 2008, 118, 1705-1712.	1.6	210
119	Effects of Icosapent Ethyl on Total Ischemic Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2791-2802.	1.2	208
120	MRI of Acute Myocarditis. <i>Chest</i> , 2002, 122, 1638-1648.	0.4	207
121	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	5.5	207
122	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127.	13.9	205
123	Comparison of Clinical Presentations and Outcomes Between Patients With <i>TGFBR2</i> and <i>FBN1</i> Mutations in Marfan Syndrome and Related Disorders. <i>Circulation</i> , 2009, 120, 2541-2549.	1.6	203
124	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011, 32, 2922-2932.	1.0	203
125	Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. <i>European Heart Journal</i> , 2009, 30, 1598-1606.	1.0	199
126	Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. <i>American Journal of Medicine</i> , 2004, 117, 73-81.	0.6	198

#	ARTICLE	IF	CITATIONS
127	Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. <i>Circulation</i> , 2013, 127, 2166-2176.	1.6	196
128	Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. <i>European Heart Journal</i> , 2009, 30, 2337-2345.	1.0	192
129	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1591.	3.8	190
130	Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. <i>Lancet, The</i> , 2016, 387, 127-135.	6.3	187
131	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1689-1700.	1.2	186
132	Impact of Prehospital Thrombolysis for Acute Myocardial Infarction on 1-Year Outcome. <i>Circulation</i> , 2004, 110, 1909-1915.	1.6	185
133	Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2010, 31, 1449-1456.	1.0	185
134	An International Model to Predict Recurrent Cardiovascular Disease. <i>American Journal of Medicine</i> , 2012, 125, 695-703.e1.	0.6	184
135	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	6.1	180
136	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2732-2740.	1.2	179
137	Inflammatory Biomarkers Interleukin-6 and C-reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of) <i>TJ ETQq1 1 0.784314 rgBT / Overlock</i>	1.0	179
138	ST-segment elevation myocardial infarction. <i>Nature Reviews Disease Primers</i> , 2019, 5, 39.	18.1	179
139	Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor. <i>Circulation</i> , 2012, 125, 978-986.	1.6	176
140	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet, The</i> , 2017, 389, 1799-1808.	6.3	174
141	Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021, 385, 297-308.	13.9	172
142	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. <i>European Heart Journal</i> , 2014, 35, 2083-2093.	1.0	171
143	Acute coronary angiographic findings in survivors of out-of-hospital cardiac arrest. <i>American Heart Journal</i> , 2009, 157, 312-318.	1.2	169
144	Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. <i>European Heart Journal</i> , 2011, 32, 2945-2953.	1.0	169

#	ARTICLE	IF	CITATIONS
145	One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008, 1, 38-45.	0.9	168
146	Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. <i>European Heart Journal</i> , 2013, 34, 1204-1214.	1.0	167
147	Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (The Global Registry of Acute Coronary Events [GRACE]). <i>American Journal of Cardiology</i> , 2004, 93, 288-293.	0.7	165
148	RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. <i>European Heart Journal</i> , 2011, 32, 2541-2554.	1.0	165
149	Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial. <i>British Journal of Anaesthesia</i> , 2011, 107, 899-910.	1.5	165
150	Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1339-1349.	3.8	161
151	The Essen Stroke Risk Score Predicts Recurrent Cardiovascular Events. <i>Stroke</i> , 2009, 40, 350-354.	1.0	156
152	Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1712-1715.	1.5	156
153	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019, 394, 1169-1180.	6.3	155
154	Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms. <i>Journal of the American College of Cardiology</i> , 2001, 37, 786-792.	1.2	154
155	Rationale and design of <scp>REDUCEâ€T</scp>: Reduction of Cardiovascular Events with Icosapent Ethylâ€Intervention Trial. <i>Clinical Cardiology</i> , 2017, 40, 138-148.	0.7	154
156	Alirocumab in Patients With Polyvascular Disease and Recent Acute CoronaryâSyndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1167-1176.	1.2	154
157	Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. <i>Lancet, The</i> , 2015, 385, 792-798.	6.3	151
158	Prevalence of Coronary Atherosclerosis in Patients With Cerebral Infarction. <i>Stroke</i> , 2011, 42, 22-29.	1.0	150
159	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction. <i>Circulation</i> , 2016, 134, 1918-1930.	1.6	148
160	Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. <i>European Heart Journal</i> , 2016, 37, 1538.1-1549.	1.0	147
161	Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. <i>Lancet, The</i> , 2012, 380, 1396-1405.	6.3	143
162	A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2000, 35, 1729-1736.	1.2	141

#	ARTICLE	IF	CITATIONS
163	Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015, 38, 696-705.	4.3	141
164	Relation Between Body Mass Index, Waist Circumference, and Death After Acute Myocardial Infarction. <i>Circulation</i> , 2008, 118, 482-490.	1.6	140
165	Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction. <i>Circulation</i> , 2011, 123, 474-482.	1.6	140
166	Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014, 35, 224-232.	1.0	140
167	Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. <i>European Heart Journal</i> , 2016, 37, ehv481.	1.0	140
168	Ischemia-Modified Albumin in Acute Stroke. <i>Cerebrovascular Diseases</i> , 2007, 23, 216-220.	0.8	139
169	Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. <i>Platelets</i> , 2014, 25, 517-525.	1.1	138
170	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y ₁₂ inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016, 37, 1133-1142.	1.0	138
171	Prevalence and Impact of Metabolic Syndrome on Hospital Outcomes in Acute Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2005, 165, 1192.	4.3	137
172	Enhanced Shear-Induced Platelet Aggregation in Patients Who Experience Subacute Stent Thrombosis. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1753-1756.	1.2	137
173	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. <i>European Heart Journal</i> , 2016, 37, 1325-1333.	1.0	137
174	Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 552.	3.8	137
175	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	0.8	133
176	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2018, 39, 1726-1735a.	1.0	133
177	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 387-396.	1.2	131
178	Angiotensin Receptor-Nephrilysin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021, 385, 1845-1855.	13.9	130
179	Autopsy Prevalence of Coronary Atherosclerosis in Patients With Fatal Stroke. <i>Stroke</i> , 2007, 38, 1203-1210.	1.0	129
180	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. <i>Lancet</i> , 2013, 382, 1879-1888.	6.3	127

#	ARTICLE	IF	CITATIONS
181	DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. <i>European Heart Journal</i> , 2004, 25, 2187-2194.	1.0	126
182	Prehospital Delay in Patients With Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). <i>Journal of the American Medical Association</i> , 2005, 294, 1010-1016.	0.7	126
183	Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrolytic Therapy vs Conventional Fibrolytic Therapy for Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 2130.	3.8	125
184	Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction. <i>Archives of Internal Medicine</i> , 2006, 166, 787.	4.3	124
185	Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease. <i>Circulation</i> , 2009, 120, 2337-2344.	1.6	123
186	Impact of Prior Peripheral Arterial Disease and Stroke on Outcomes of Acute Coronary Syndromes and Effect of Evidence-Based Therapies (from the Global Registry of Acute Coronary Events). <i>American Journal of Cardiology</i> , 2007, 100, 1-6.	0.7	122
187	Adherence to Secondary Prevention Medications and Four-year Outcomes in Outpatients with Atherosclerosis. <i>American Journal of Medicine</i> , 2013, 126, 693-700.e1.	0.6	121
188	Stroke and Outcomes in Patients With Acute Type A Aortic Dissection. <i>Circulation</i> , 2013, 128, S175-9.	1.6	120
189	Pulse Pressure and Risk for Cardiovascular Events in Patients With Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2016, 67, 392-403.	1.2	120
190	Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. <i>European Heart Journal</i> , 2010, 31, 1257-1265.	1.0	119
191	Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2013, 128, 1055-1065.	1.6	118
192	Prevalence of Anginal Symptoms and Myocardial Ischemia and Their Effect on Clinical Outcomes in Outpatients With Stable Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2014, 174, 1651.	2.6	118
193	Effect of Radial Versus Femoral Access on Radiation Dose and the Importance of Procedural Volume. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 258-266.	1.1	117
194	Myocardial infarction after aspirin cessation in stable coronary artery disease patients. <i>International Journal of Cardiology</i> , 2000, 76, 257-258.	0.8	116
195	The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. <i>Journal of the American Medical Association</i> , 2011, 306, 1014-1024.	1.0	114
196	Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. <i>American Journal of Cardiology</i> , 2005, 95, 509-510.	0.7	114
197	Five-Year Survival in Patients With ST-Segment Elevation Myocardial Infarction According to Modalities of Reperfusion Therapy. <i>Circulation</i> , 2014, 129, 1629-1636.	1.6	114
198	Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention. <i>Circulation</i> , 2005, 111, 1390-1397.	1.6	113

#	ARTICLE	IF	CITATIONS
199	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj 5 patients with coronary heart disease. American Heart Journal, 2010, 160, 655-661.e2.	1.2	111
200	Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19. JAMA Internal Medicine, 2021, 181, 1241.	2.6	111
201	Circulating Secretary Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary Syndromes. Journal of the American College of Cardiology, 2005, 46, 1249-1257.	1.2	110
202	The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention. Journal of the American College of Cardiology, 2009, 54, 678-685.	1.2	109
203	Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart, 2012, 98, 195-201.	1.2	109
204	Living Alone and Cardiovascular Risk in Outpatients at Risk of or With Atherothrombosis. Archives of Internal Medicine, 2012, 172, 1086.	4.3	109
205	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet, The, 2016, 387, 349-356.	6.3	109
206	Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Journal of the American College of Cardiology, 2017, 69, 2011-2022.	1.2	109
207	Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. European Heart Journal, 2008, 30, 321-329.	1.0	108
208	Unprotected left main revascularization in patients with acute coronary syndromes. European Heart Journal, 2009, 30, 2308-2317.	1.0	108
209	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. American Heart Journal, 2016, 182, 125-134.	1.2	108
210	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. Journal of the American College of Cardiology, 2016, 67, 1145-1154.	1.2	108
211	Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and) Tj ETQq1 1 0.784314 rgBT /Overlock 107 2009. 103. 1359-1363.	0.7	107
212	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. European Heart Journal, 2015, 36, 1901-1912.	1.0	107
213	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019, 140, 103-112.	1.6	107
214	Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). American Heart Journal, 2003, 146, 999-1006.	1.2	104
215	REDUCE-IT USA. Circulation, 2020, 141, 367-375.	1.6	104
216	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. Circulation, 2020, 141, 1608-1617.	1.6	104

#	ARTICLE	IF	CITATIONS
217	The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: Lessons from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2006, 151, 654-660.	1.2	101
218	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2223-2234.	1.2	101
219	Comparison of the prognostic value of C-Reactive protein and troponin I in patients with unstable angina pectoris. <i>American Journal of Cardiology</i> , 1998, 82, 845-850.	0.7	100
220	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization. <i>Circulation</i> , 2014, 129, 293-303.	1.6	100
221	Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. <i>European Heart Journal</i> , 2011, 32, 41-50.	1.0	99
222	Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2213-2223.	1.2	99
223	Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2008, 118, 2038-2046.	1.6	98
224	The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. <i>American Heart Journal</i> , 2011, 162, 818-825.e6.	1.2	98
225	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. <i>Clinical Chemistry</i> , 2017, 63, 325-333.	1.5	97
226	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 1092.	3.0	97
227	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1841-1854.	1.6	96
228	Medication performance measures and mortality following acute coronary syndromes. <i>American Journal of Medicine</i> , 2005, 118, 858-865.	0.6	95
229	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 813-826.	1.2	95
230	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. <i>European Heart Journal</i> , 2019, 40, 2595-2604.	1.0	93
231	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	1.0	93
232	Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 541-550.	0.8	92
233	Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 619-629.	1.2	92
234	Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2016, 12, 1239-1245.	1.4	92

#	ARTICLE	IF	CITATIONS
235	Ethnic Differences in Cardiovascular Risks and Mortality in Atherothrombotic Disease: Insights From the REduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Mayo Clinic Proceedings</i> , 2011, 86, 960-967.	1.4	90
236	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin—Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. <i>American Heart Journal</i> , 2014, 167, 437-444.e5.	1.2	89
237	Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina. <i>American Heart Journal</i> , 1999, 137, 815-820.	1.2	88
238	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. <i>JAMA Cardiology</i> , 2016, 1, 425.	3.0	88
239	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	6.1	87
240	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. <i>European Heart Journal</i> , 2012, 33, 2143-2150.	1.0	86
241	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehw454.	1.0	86
242	The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: A pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. <i>American Heart Journal</i> , 2011, 161, 283-290.	1.2	85
243	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. <i>European Heart Journal</i> , 2013, 34, 2263-2270.	1.0	85
244	Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. <i>European Heart Journal</i> , 2009, 30, 549-557.	1.0	84
245	β-Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 872-881.	0.9	84
246	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019, 140, 2054-2062.	1.6	83
247	Prevalence, Awareness and Treatment of Cardiovascular Risk Factors in Patients at High Risk of Atherothrombosis in Japan Results From Domestic Baseline Data of the REduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Circulation Journal</i> , 2007, 71, 995-1003.	0.7	82
248	Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary Stents. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1113.	3.8	82
249	Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 734-742.	0.8	82
250	Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: Insights from the International RealiseAF Survey. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 77-87.	0.7	81
251	Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. <i>American Journal of Medicine</i> , 2015, 128, 766-775.	0.6	81
252	Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. <i>International Journal of Cardiology</i> , 2011, 146, 408-414.	0.8	80

#	ARTICLE	IF	CITATIONS
253	Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1623-1630.	1.2	80
254	Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. <i>European Heart Journal</i> , 2014, 35, 2460-2467.	1.0	80
255	Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). <i>American Journal of Cardiology</i> , 2003, 91, 925-930.	0.7	79
256	Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morbidity-mortality Evaluation of the If inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) Study. <i>American Heart Journal</i> , 2006, 152, 860-866.	1.2	79
257	Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1159-1161.	1.2	79
258	Uncovering Heart Failure in Patients with a History of Pulmonary Disease: Rationale for the Early Use of B-type Natriuretic Peptide in the Emergency Department. <i>Academic Emergency Medicine</i> , 2003, 10, 198-204.	0.8	78
259	DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2492-2502.	1.2	78
260	Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk. <i>JAMA Cardiology</i> , 2018, 3, 155.	3.0	78
261	Study design and rationale for the Stabilization of pLaques using Darapladib Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. <i>American Heart Journal</i> , 2011, 162, 613-619.e1.	1.2	77
262	Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 214-220.	1.1	77
263	Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk. <i>JAMA Cardiology</i> , 2016, 1, 989.	3.0	77
264	B-Type Natriuretic Peptide and Echocardiographic Determination of Ejection Fraction in the Diagnosis of Congestive Heart Failure in Patients With Acute Dyspnea. <i>Chest</i> , 2005, 128, 21-29.	0.4	75
265	Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry. <i>Vascular Medicine</i> , 2010, 15, 259-265.	0.8	75
266	Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: Data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Journal of Vascular Medicine and Biology</i> , 2008, 20, 808-814.e1.	0.6	74
267	Impact of Collateral Flow to the Occluded Infarct-Related Artery on Clinical Outcomes in Patients With Recent Myocardial Infarction: A Report From the Randomized Occluded Artery Trial. <i>Circulation</i> , 2010, 121, 2724-2730.	1.6	74
268	Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTEMI/ACS): insights from the Global Registry of Acute Coronary Events. <i>Heart</i> , 2011, 97, 197-202.	1.2	74
269	A History of Stroke/Transient Ischemic Attack Indicates High Risks of Cardiovascular Event and Hemorrhagic Stroke in Patients With Coronary Artery Disease. <i>Circulation</i> , 2013, 127, 730-738.	1.6	74
270	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in the PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1368-1375.	1.2	74

#	ARTICLE	IF	CITATIONS
271	Predictors of Long-term Adherence to Evidence-based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the REACH Registry. <i>Clinical Cardiology</i> , 2013, 36, 721-727.	0.7	72
272	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <i>European Heart Journal</i> , 2018, 39, 750-757a.	1.0	72
273	Bleeding avoidance strategies in percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 117-132.	6.1	71
274	Heart Rate and Use of Beta-Blockers in Stable Outpatients with Coronary Artery Disease. <i>PLoS ONE</i> , 2012, 7, e36284.	1.1	70
275	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATElet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2014, 35, 1541-1550.	1.0	70
276	Procedural Volume and Outcomes With Radial or Femoral Access for Coronary Angiography and Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 954-963.	1.2	70
277	Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction. <i>Circulation</i> , 2019, 140, 1004-1014.	1.6	70
278	An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. <i>European Heart Journal</i> , 2007, 28, 2200-2207.	1.0	68
279	Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 580-589.	3.3	68
280	Regional and Practice Variation in Adherence to Guideline Recommendations for Secondary and Primary Prevention Among Outpatients With Atherothrombosis or Risk Factors in the United States. <i>Critical Pathways in Cardiology</i> , 2009, 8, 104-111.	0.2	68
281	Prevalence of Systemic Atherosclerosis Burdens and Overlapping Stroke Etiologies and Their Associations With Long-term Vascular Prognosis in Stroke With Intracranial Atherosclerotic Disease. <i>JAMA Neurology</i> , 2018, 75, 203.	4.5	68
282	Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines. <i>Journal of the American College of Cardiology</i> , 2009, 54, 468-476.	1.2	67
283	Design and rationale of the TOTAL trial: A randomized trial of routine aspiration Thrombectomy with percutaneous coronary intervention (PCI) versus PCI Alone in patients with ST-elevation myocardial infarction undergoing primary PCI. <i>American Heart Journal</i> , 2014, 167, 315-321.e1.	1.2	66
284	β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. <i>European Heart Journal</i> , 2019, 40, 1399-1407.	1.0	66
285	High cardiovascular event rates in patients with asymptomatic carotid stenosis: the REACH registry*. <i>European Journal of Neurology</i> , 2009, 16, 902-908.	1.7	65
286	Carotid Atherosclerosis and Risk of Subsequent Coronary Event in Outpatients With Atherothrombosis. <i>Stroke</i> , 2013, 44, 373-379.	1.0	65
287	Design and Rationale of the REDUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etxilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. <i>Clinical Cardiology</i> , 2016, 39, 555-564.	0.7	65
288	Comparison of direct coronary stenting with and without balloon predilatation in patients with stable angina pectoris. <i>American Journal of Cardiology</i> , 2001, 87, 693-698.	0.7	64

#	ARTICLE	IF	CITATIONS
289	Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease. <i>International Journal of Cardiology</i> , 2013, 167, 2938-2943.	0.8	64
290	Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. <i>International Journal of Cardiology</i> , 2014, 170, 413-418.	0.8	64
291	The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1240-1248.	1.8	64
292	Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. <i>European Heart Journal</i> , 2008, 29, 462-471.	1.0	63
293	Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2010, 31, 667-675.	1.0	63
294	Incomplete Resolution of ST-Segment Elevation Is a Marker of Transient Microcirculatory Dysfunction After Stenting for Acute Myocardial Infarction. <i>Circulation</i> , 2003, 107, 2684-2689.	1.6	62
295	Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2015, 65, 27-38.	1.2	62
296	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. <i>European Heart Journal</i> , 2019, 40, 1553-1562.	1.0	62
297	A Study of Biochemical Markers of Reperfusion Early After Thrombolysis for Acute Myocardial Infarction. <i>Circulation</i> , 1995, 92, 2079-2086.	1.6	62
298	High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2015, 36, 976-983.	1.0	61
299	Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). <i>American Journal of Cardiology</i> , 2010, 105, 667-671.	0.7	60
300	Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function) <i>TJ ETQq0 0 0 rgBT /Overlock 106 of 50 297</i>		
301	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021, 231, 121-127.	1.2	60
302	Risk Factor Profile and Management of Cerebrovascular Patients in the REACH Registry. <i>Cerebrovascular Diseases</i> , 2008, 25, 366-374.	0.8	59
303	Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry. <i>European Heart Journal</i> , 2008, 29, 3052-3060.	1.0	59
304	Effect of Paraoxonase-1 Polymorphism on Clinical Outcomes in Patients Treated With Clopidogrel After an Acute Myocardial Infarction. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 561-567.	2.3	59
305	Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kidsâ€™DOTT trial): pilot/feasibility phase findings. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1597-1605.	1.9	59
306	Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. <i>Lancet</i> , The, 2015, 386, 292-302.	6.3	59

#	ARTICLE	IF	CITATIONS
307	Prognosis of Atrial Fibrillation in Patients with Symptomatic Peripheral Arterial Disease: Data from the REduction of Atherothrombosis for Continued Health (REACH) Registry. <i>European Journal of Vascular and Endovascular Surgery</i> , 2010, 40, 9-16.	0.8	58
308	Anticoagulation With Otamixaban and Ischemic Events in Non- σ ST-Segment Elevation Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1145.	3.8	58
309	Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: perspective on glucose-lowering interventions. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 238-244.	2.2	58
310	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021, 78, 421-433.	1.2	58
311	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2018, 3, 1160.	3.0	57
312	Early changes in myocardial perfusion patterns after myocardial infarction: relation with contractile reserve and functional recovery. <i>Journal of the American College of Cardiology</i> , 1998, 32, 2011-2017.	1.2	56
313	Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study). <i>American Journal of Cardiology</i> , 2004, 94, 1543-1547.	0.7	56
314	Fondaparinux versus Enoxaparin in non- σ ST-elevation acute coronary syndromes: Short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. <i>American Heart Journal</i> , 2009, 157, 845-852.	1.2	56
315	Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH]) <i>Tj ETQq1 1 0.784314 rgt / Over</i>	0.7	56
316	Attained Educational Level and Incident Atherothrombotic Events in Low- and Middle-Income Compared With High-Income Countries. <i>Circulation</i> , 2010, 122, 1167-1175.	1.6	56
317	Two-year Vascular Hospitalisation Rates and Associated Costs in Patients at Risk of Atherothrombosis in France and Germany: Highest Burden for Peripheral Arterial Disease. <i>European Journal of Vascular and Endovascular Surgery</i> , 2012, 43, 198-207.	0.8	56
318	Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. <i>Heart</i> , 2016, 102, 617-625.	1.2	56
319	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 489-496.	1.2	56
320	2012 ESC STEMI guidelines and reperfusion therapy. <i>Heart</i> , 2013, 99, 1156-1157.	1.2	55
321	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. <i>European Heart Journal</i> , 2020, 41, 347-356.	1.0	55
322	Reperfusion syndrome: relationship of coronary blood flow reserve to left ventricular function and infarct size. <i>Journal of the American College of Cardiology</i> , 2000, 35, 1162-1169.	1.2	54
323	Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial. <i>European Heart Journal</i> , 2014, 35, 2812-2820.	1.0	54
324	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1349-1357.	1.1	54

#	ARTICLE	IF	CITATIONS
325	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2017, 185, 140-149.	1.2	54
326	Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model. <i>Journal of the American Heart Association</i> , 2018, 7, e009217.	1.6	54
327	Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. <i>EuroIntervention</i> , 2015, 11, 737-745.	1.4	54
328	Antithrombotics in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 54, 969-984.	1.2	53
329	Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: Results from 1-year outcomes in the Japanese REACH Registry. <i>Journal of the Neurological Sciences</i> , 2009, 287, 45-51.	0.3	53
330	Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	53
331	Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2015, 116, 686-693.	0.7	52
332	Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: An expert consensus*. <i>American Heart Journal</i> , 2002, 144, 615-624.	1.2	51
333	Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI) time. <i>American Journal of Cardiology</i> , 2003, 91, 1401-1405.	0.7	51
334	Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. <i>European Heart Journal</i> , 2008, 30, 183-191.	1.0	51
335	Renal function, atherothrombosis extent, and outcomes in high-risk patients. <i>American Heart Journal</i> , 2009, 158, 141-148.e1.	1.2	51
336	Coronary Artery Disease and Risk of Major Vascular Events After Cerebral Infarction. <i>Stroke</i> , 2013, 44, 1505-1511.	1.0	51
337	Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1552-1562.	1.1	51
338	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 674-684.	1.1	51
339	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. <i>European Heart Journal</i> , 2020, 41, 2248-2258.	1.0	51
340	The Dispatch™ catheter as a delivery tool for arterial gene transfer. <i>Cardiovascular Research</i> , 1997, 33, 181-187.	1.8	50
341	Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1056-1065.	0.8	50
342	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3140-3147.	1.2	50

#	ARTICLE	IF	CITATIONS
343	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 162-171.	1.2	50
344	Does Preventive PCI Work?. <i>New England Journal of Medicine</i> , 2007, 356, 1572-1574.	13.9	49
345	Thrombocytopenia in Patients With an Acute Coronary Syndrome (from the Global Registry of Acute) Tj ETQq1 1 0.784314 rgBT /Overd	0.7	49
346	Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 138-147.	1.1	49
347	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial. <i>European Heart Journal</i> , 2018, 39, 4112-4121.	1.0	49
348	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1177-1186.	1.2	49
349	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 21.	3.0	49
350	Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes. <i>EuroIntervention</i> , 2011, 7, 91-97.	1.4	49
351	Impact of In-Hospital Revascularization on Survival in Patients With Non-ST-Elevation Acute Coronary Syndrome and Congestive Heart Failure. <i>Circulation</i> , 2008, 118, 1163-1171.	1.6	48
352	Epicardial Adipose Tissue Thickness Correlates with the Presence and Severity of Angiographic Coronary Artery Disease in Stable Patients with Chest Pain. <i>PLoS ONE</i> , 2014, 9, e110005.	1.1	48
353	Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis. <i>European Heart Journal</i> , 2015, 36, 2716-2728.	1.0	48
354	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2297-2308.	1.2	48
355	Risk Stratification in Non-ST-segment Elevation Acute Coronary Syndromes: Troponin Alone Is not Enough. <i>American Journal of Medicine</i> , 2009, 122, 107-108.	0.6	47
356	Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe. <i>Heart</i> , 2011, 97, 660-667.	1.2	47
357	Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?. <i>European Heart Journal</i> , 2013, 34, 1630-1635.	1.0	47
358	Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1493-1499.	1.2	47
359	Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. <i>Circulation</i> , 2016, 133, 1772-1782.	1.6	47
360	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 176-185.	1.2	47

#	ARTICLE	IF	CITATIONS
361	Current status of cardiovascular laser therapy, 1987. IEEE Journal of Quantum Electronics, 1987, 23, 1756-1771.	1.0	46
362	Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial. European Heart Journal, 1999, 20, 1572-1578.	1.0	46
363	A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. International Journal of Cardiology, 2001, 77, 263-273.	0.8	46
364	Design and rationale of the Radial Vs. femoral access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. American Heart Journal, 2011, 161, 254-260.e4.	1.2	46
365	In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis. European Heart Journal, 2012, 33, 252-263.	1.0	46
366	Fate of individuals with ischemic amputations in the REACH Registry: Three-year cardiovascular and limb-related outcomes. Atherosclerosis, 2012, 221, 527-535.	0.4	46
367	Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)â€¦IMI 53 trial. Diabetes/Metabolism Research and Reviews, 2013, 29, 417-426.	1.7	46
368	Reduction in Revascularization With Icosapent Ethyl. Circulation, 2021, 143, 33-44.	1.6	46
369	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. Circulation, 2021, 143, 1109-1122.	1.6	46
370	The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. European Heart Journal, 2008, 30, 857-865.	1.0	45
371	One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry. Canadian Journal of Cardiology, 2010, 26, e297-e305.	0.8	45
372	Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. European Heart Journal, 2014, 35, 1932-1948.	1.0	45
373	Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or <sc>TIA</sc>: Insights From the <sc>REACH</sc> Registry. Clinical Cardiology, 2016, 39, 670-677.	0.7	45
374	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. European Heart Journal, 2017, 38, 2813-2822.	1.0	45
375	Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. European Heart Journal, 2018, 39, 2255-2262.	1.0	45
376	Effect and Safety of Morphine Use in Acute Anterior STâ€¦Segment Elevation Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	1.6	45
377	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 2019, 40, 2801-2809.	1.0	45
378	Primary coronary angioplasty for acute myocardial infarction with contraindication to thrombolysis. American Journal of Cardiology, 1993, 71, 377-381.	0.7	44

#	ARTICLE	IF	CITATIONS
379	A matched comparison of the combination of prehospital thrombolysis and standby rescue angioplasty with primary angioplasty. <i>American Journal of Cardiology</i> , 1999, 83, 305-310.	0.7	44
380	The French randomized optimal stenting trial: a prospective evaluation of provisional stenting guided by coronary velocity reserve and quantitative coronary angiography. <i>Journal of the American College of Cardiology</i> , 2000, 36, 404-409.	1.2	44
381	Lipoproteinâ€Associated Phospholipase A ₂ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	44
382	Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1954-1962.	1.1	44
383	Efficacy of Streptokinase, but Not Tissue-Type Plasminogen Activator, in Achieving 90-Minute Patency After Thrombolysis for Acute Myocardial Infarction Decreases With Time to Treatment. <i>Journal of the American College of Cardiology</i> , 1998, 31, 776-779.	1.2	43
384	NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease. <i>American Journal of Medicine</i> , 2014, 127, 53-60.e1.	0.6	43
385	Vitamin K antagonists with or without longâ€term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. <i>Clinical Cardiology</i> , 2017, 40, 932-939.	0.7	43
386	Rationale and design of the Patient Related Outcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. <i>American Heart Journal</i> , 2009, 158, 902-909.e5.	1.2	42
387	Overlap of Diseases Underlying Ischemic Stroke. <i>Stroke</i> , 2013, 44, 2427-2433.	1.0	42
388	Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2011, 162, 98-105.e1.	1.2	41
389	Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. <i>Human Molecular Genetics</i> , 2016, 25, 1447-1456.	1.4	41
390	Relationships Between Components of Blood Pressure and Cardiovascular Events in Patients with Stable Coronary Artery Disease and Hypertension. <i>Hypertension</i> , 2018, 71, 168-176.	1.3	41
391	Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2020, 51, 2066-2075.	1.0	41
392	Response to Letter Regarding Article, â€Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concernâ€• <i>Circulation</i> , 2007, 116, .	1.6	40
393	Comparisons of Guideline-Recommended Therapies in Patients With Documented Coronary Artery Disease Having Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Versus Medical Therapy Only (from the REACH International Registry). <i>American Journal of Cardiology</i> , 2007, 99, 1212-1215.	0.7	40
394	C-reactive protein levels in patients at cardiovascular risk: EURIKA study. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 25.	0.7	40
395	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. <i>Circulation</i> , 2016, 134, 861-871.	1.6	40
396	Rationale, design, and baseline characteristics of the <sc>CLARIFY</sc> registry of outpatients with stable coronary artery disease. <i>Clinical Cardiology</i> , 2017, 40, 797-806.	0.7	40

#	ARTICLE	IF	CITATIONS
397	Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. <i>European Heart Journal</i> , 2022, 43, 1715-1727.	1.0	40
398	Are the Results of Primary Percutaneous Transluminal Coronary Angioplasty for Acute Myocardial Infarction Different During the "Off-Hours?". <i>American Journal of Cardiology</i> , 1997, 79, 1527-1529.	0.7	39
399	ST-Elevation Acute Coronary Syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Circulation</i> , 2012, 125, 514-521.	1.6	39
400	Global Variation in the Prevalence of Elevated Cholesterol in Outpatients With Established Vascular Disease or 3 Cardiovascular Risk Factors According to National Indices of Economic Development and Health System Performance. <i>Circulation</i> , 2012, 125, 1858-1869.	1.6	39
401	Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 270-279.	0.4	39
402	PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 28-38.	1.4	39
403	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020, 141, 1141-1151.	1.6	39
404	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. <i>Circulation</i> , 2021, 144, 1845-1855.	1.6	39
405	Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1083-1091.	1.1	38
406	Relation between body mass index, waist circumference, and cardiovascular outcomes in 19,579 diabetic patients with established vascular disease: the REACH Registry. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 241-249.	0.8	38
407	Cystatin C and Estimated Glomerular Filtration Rate as Predictors for Adverse Outcome in Patients with ST-Elevation and Non-ST-Elevation Acute Coronary Syndromes: Results from the Platelet Inhibition and Patient Outcomes Study. <i>Clinical Chemistry</i> , 2012, 58, 190-199.	1.5	38
408	Causes of late mortality with dual antiplatelet therapy after coronary stents. <i>European Heart Journal</i> , 2015, 37, ehv614.	1.0	38
409	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1905-1913.	1.1	38
410	Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery Disease. <i>American Journal of Medicine</i> , 2017, 130, 720-730.	0.6	38
411	Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 942-954.	1.1	38
412	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. <i>Heart</i> , 2017, 103, 1339-1346.	1.2	38
413	Combined Abciximab Reteplase Stent Study in acute myocardial infarction (CARESS in AMI). <i>American Heart Journal</i> , 2004, 148, 378-385.	1.2	37
414	Ethnic differences in the relationships of anthropometric measures to metabolic risk factors in Asian patients at risk of atherothrombosis. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 400-408.	1.5	37

#	ARTICLE	IF	CITATIONS
415	Influenza vaccination and cardiovascular risk in patients with recent TIA and stroke. <i>Neurology</i> , 2014, 82, 1905-1913.	1.5	37
416	Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. <i>European Heart Journal</i> , 2015, 36, ehv451.	1.0	37
417	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e002490.	1.6	37
418	Future of the Prevention and Treatment of Coronary Artery Disease. <i>Circulation Journal</i> , 2016, 80, 1067-1072.	0.7	37
419	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1461-1469.	1.1	37
420	Prognostic value of the infarct- and non-infarct like patterns and cardiovascular magnetic resonance parameters on long-term outcome of patients after acute myocarditis. <i>International Journal of Cardiology</i> , 2016, 212, 63-69.	0.8	37
421	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 129.	3.8	37
422	Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2009, 101, 734-740.	1.8	36
423	Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: Insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>American Heart Journal</i> , 2009, 158, 1038-1045.	1.2	36
424	Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: Results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. <i>American Heart Journal</i> , 2012, 163, 563-571.	1.2	36
425	Comparison of Acute Coronary Syndrome in Patients Receiving Versus Not Receiving Chronic Dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). <i>American Journal of Cardiology</i> , 2012, 109, 19-25.	0.7	36
426	Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from the Tj ETQq0 0 0 rBT /Overlock 10 Tf 0.7)	0.7	36
427	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. <i>American Heart Journal</i> , 2017, 186, 91-99.	1.2	36
428	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors. <i>JAMA Cardiology</i> , 2017, 2, 127.	3.0	36
429	Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3281-3291.	1.2	36
430	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. <i>Atherosclerosis</i> , 2020, 295, 45-53.	0.4	36
431	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. <i>Circulation</i> , 2021, 144, 1750-1759.	1.6	36
432	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1660-1671.	1.2	36

#	ARTICLE	IF	CITATIONS
433	Impact of polyvascular disease on baseline characteristics, management and mortality in acute myocardial infarction. The Alliance project. Archives of Cardiovascular Diseases, 2010, 103, 207-214.	0.7	35
434	Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC: Cardiovascular Interventions, 2013, 6, 671-683.	1.1	35
435	Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin. JACC: Cardiovascular Interventions, 2015, 8, 424-433.	1.1	35
436	In-hospital outcomes and long-term mortality according to sex and management strategy in acute myocardial infarction. Insights from the French ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) 2005 Registry. International Journal of Cardiology, 2015, 201, 265-270.	0.8	35
437	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. European Heart Journal, 2020, 41, 4114-4123.	1.0	35
438	Percutaneous, in vivo excimer laser angioplasty: Results in two experimental animal models. Lasers in Surgery and Medicine, 1988, 8, 223-232.	1.1	34
439	Limits of reperfusion therapy for immediate cardiogenic shock complicating acute myocardial infarction. American Journal of Cardiology, 1994, 74, 492-494.	0.7	34
440	Comparison using dynamic vectorcardiography and MIBI SPECT of ST-segment changes and myocardial MIBI uptake during percutaneous transluminal coronary angioplasty of the left anterior descending coronary artery. American Journal of Cardiology, 1995, 75, 998-1002.	0.7	34
441	Safety of Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction (from the BEAUTIFUL Holter Substudy). American Journal of Cardiology, 2011, 107, 805-811.	0.7	34
442	Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in Europe. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 270-277.	3.1	34
443	Outcomes of a Pharmacoinvasive Strategy for Successful Versus Failed Fibrinolysis and Primary Percutaneous Intervention in Acute Myocardial Infarction (from the Strategic Reperfusion Early) Tj ETQq1 1 0.78430.4 rgBT /Overlock 10	0.7	34
444	Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?. American Heart Journal, 2014, 168, 611-621.	1.2	34
445	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. American Journal of Medicine, 2016, 129, 340.e1-340.e8.	0.6	34
446	Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2019, 73, 1362-1364.	1.2	34
447	Real-Life Benefits of Statins for Cardiovascular Prevention in Elderly Subjects: A Population-Based Cohort Study. American Journal of Medicine, 2019, 132, 740-748.e7.	0.6	34
448	Determinants of improved one-year survival in non-ST-segment elevation myocardial infarction patients: Insights from the French FAST-MI program over 15years. International Journal of Cardiology, 2014, 177, 281-286.	0.8	33
449	Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry. Clinical Cardiology, 2017, 40, 710-718.	0.7	33
450	Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria. European Heart Journal, 2017, 38, 3211-3218.	1.0	33

#	ARTICLE	IF	CITATIONS
451	The paradox of cholesterol and stroke. <i>Lancet</i> , The, 2007, 370, 1803-1804.	6.3	32
452	Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. <i>American Heart Journal</i> , 2009, 158, 881-886.e1.	1.2	32
453	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris) on Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2015, 116, 845-852.	0.7	32
454	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1890-1901.	1.1	32
455	Usefulness of Late Iodine Enhancement on Spectral CT in Acute Myocarditis. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 826-827.	2.3	32
456	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	32
457	Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e015331.	1.6	32
458	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021, 143, 470-478.	1.6	32
459	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	2.0	32
460	Can We Provide Reperfusion Therapy to All Unselected Patients Admitted With Acute Myocardial Infarction?. <i>Journal of the American College of Cardiology</i> , 1997, 30, 157-164.	1.2	31
461	Rationale and design of the Losmapimod To Inhibit p38 MAP kinase as a Therapeutic target and modify outcomes after an acute coronary syndrome trial. <i>American Heart Journal</i> , 2015, 169, 622-630.e6.	1.2	31
462	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions. <i>Circulation</i> , 2016, 134, 723-733.	1.6	31
463	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 28-38.	1.1	31
464	Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 721-733.	1.2	31
465	Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. <i>Journal of the American Heart Association</i> , 2021, 10, e022125.	1.6	31
466	Patterns of myoglobin and MM creatine kinase isoforms release early after intravenous thrombolysis or direct percutaneous transluminal coronary angioplasty for acute myocardial infarction, and implications for the early noninvasive diagnosis of reperfusion. <i>American Journal of Cardiology</i> , 1992, 70, 1129-1134.	0.7	30
467	Patterns of use and potential impact of early β -blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: The Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2006, 152, 1015-1021.	1.2	30
468	Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. <i>Archives of Cardiovascular Diseases</i> , 2009, 102, 485-496.	0.7	30

#	ARTICLE	IF	CITATIONS
469	Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. <i>International Journal of Cardiology</i> , 2014, 176, 119-124.	0.8	30
470	Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap. <i>American Heart Journal</i> , 2015, 170, 3-12.	1.2	30
471	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 829-844.	6.1	30
472	A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2005, 150, 401.e1-401.e7.	1.2	29
473	Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 116, 544-553.	1.8	29
474	A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. <i>American Heart Journal</i> , 2016, 174, 120-128.	1.2	29
475	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). <i>European Heart Journal</i> , 2016, 37, 152-160.	1.0	29
476	Timing of Angiography and Outcomes in High-Risk Patients With Non-“ST-Segment” Elevation Myocardial Infarction Managed Invasively. <i>Circulation</i> , 2017, 136, 1895-1907.	1.6	29
477	Identifying needs and opportunities for advancing translational research in cardiovascular disease. <i>Cardiovascular Research</i> , 2009, 83, 425-435.	1.8	28
478	Late Outcomes After Carotid Artery Stenting Versus Carotid Endarterectomy. <i>Circulation</i> , 2010, 122, 1091-1100.	1.6	28
479	Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. <i>BMC Public Health</i> , 2011, 11, 704.	1.2	28
480	Risk factors and outcomes for patients with vascular disease and serious bleeding events. <i>Heart</i> , 2011, 97, 1507-1512.	1.2	28
481	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 68-76.	1.1	28
482	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1145-1155.	1.2	28
483	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2022, 145, 87-89.	1.6	28
484	Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away From Morbidity and Mortality?. <i>Journal of Cardiac Failure</i> , 2009, 15, 199-205.	0.7	27
485	Myocardial infarction after blunt chest trauma: usefulness of cardiac ECG-gated CT and MRI for positive and aetiologic diagnosis. <i>Emergency Radiology</i> , 2011, 18, 271-274.	1.0	27
486	Two-Year Vascular Event Rates in Patients with Symptomatic Cerebrovascular Disease: The REACH Registry. <i>Cerebrovascular Diseases</i> , 2011, 32, 254-260.	0.8	27

#	ARTICLE	IF	CITATIONS
487	The future of clinical trials in secondary prevention after acute coronary syndromes. <i>European Heart Journal</i> , 2011, 32, 1583-1589.	1.0	27
488	Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. <i>American Heart Journal</i> , 2013, 166, 654-661.e6.	1.2	27
489	An Education Program for Risk Factor Management After an Acute Coronary Syndrome. <i>JAMA Internal Medicine</i> , 2014, 174, 40.	2.6	27
490	Growth Differentiation Factor 15 at 1ÂMonth After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	27
491	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2020, 41, 1625-1632.	1.0	27
492	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020, 5, 1255.	3.0	27
493	Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 317-322.	1.0	26
494	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 248-255.	1.6	26
495	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Nonâ€ST-Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017, 63, 573-584.	1.5	26
496	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCEâ€PCI. <i>Journal of the American Heart Association</i> , 2022, 11, e022937.	1.6	26
497	Stroke is a coronary heart disease risk equivalent: implications for future clinical trials in secondary stroke prevention. <i>European Heart Journal</i> , 2008, 29, 1605-1607.	1.0	25
498	Cardiac diffusionâ€weighted MR imaging in recent, subacute, and chronic myocardial infarction: A pilot study. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 1377-1387.	1.9	25
499	Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1509-1516.	0.8	25
500	Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. <i>European Heart Journal</i> , 2014, 35, 1760-1768.	1.0	25
501	Blood transfusion, bleeding, anemia, and survival in patients with acute myocardial infarction: FAST-MI registry. <i>American Heart Journal</i> , 2015, 170, 726-734.e2.	1.2	25
502	NLR4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 498-506.	5.1	25
503	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. <i>American Heart Journal</i> , 2016, 180, 22-28.	1.2	25
504	On the use of propensity scores in case of rare exposure. <i>BMC Medical Research Methodology</i> , 2016, 16, 38.	1.4	25

#	ARTICLE	IF	CITATIONS
505	Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding. <i>Journal of the American College of Cardiology</i> , 2016, 67, 596-598.	1.2	25
506	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 855.	3.0	25
507	Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. <i>Diabetes Care</i> , 2018, 41, 577-585.	4.3	25
508	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 200-206.	1.4	25
509	Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). <i>American Journal of Cardiology</i> , 2019, 123, 145-152.	0.7	25
510	International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. <i>Circulation</i> , 2021, 144, 512-523.	1.6	25
511	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1525-1537.	1.2	25
512	Determinants of use and outcomes of invasive coronary procedures in acute coronary syndromes: results from ENACT. <i>European Heart Journal</i> , 2003, 24, 613-622.	1.0	24
513	Is primary angioplasty more effective than prehospital fibrinolysis in diabetics with acute myocardial infarction? Data from the CAPTIM randomized clinical trial. <i>European Heart Journal</i> , 2005, 26, 1712-1718.	1.0	24
514	Increasing Use of Single and Combination Medical Therapy in Patients Hospitalized for Acute Myocardial Infarction in the 21st Century_{title}>A Multinational Perspective</sub>. <i>Archives of Internal Medicine</i> , 2007, 167, 1766.	4.3	24
515	Aortic arch atheroma in transient ischemic attack patients. <i>Atherosclerosis</i> , 2013, 231, 124-128.	0.4	24
516	Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction. <i>American Journal of Medicine</i> , 2015, 128, 1102-1108.e6.	0.6	24
517	Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: A multicenter study. <i>International Journal of Cardiology</i> , 2016, 220, 137-142.	0.8	24
518	Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. <i>International Journal of Cardiology</i> , 2017, 241, 87-96.	0.8	24
519	Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. <i>American Heart Journal</i> , 2017, 183, 91-101.	1.2	24
520	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006144.	1.4	24
521	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. <i>Clinical Cardiology</i> , 2019, 42, 498-505.	0.7	24
522	Heart Failure in Patients With Atrial Fibrillation Is Associated With a High Symptom and Hospitalization Burden: The <sc>RealiseAF</sc> Survey. <i>Clinical Cardiology</i> , 2013, 36, 766-774.	0.7	23

#	ARTICLE	IF	CITATIONS
523	Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. <i>Heart</i> , 2015, 101, 692-698.	1.2	23
524	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2016, 177, 1-8.	1.2	23
525	The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. <i>European Heart Journal</i> , 2016, 37, 1122-1130.	1.0	23
526	Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 527-538.	1.2	23
527	Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2015-2027.	1.2	23
528	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 216-226.	1.4	23
529	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e61-e63.	1.4	23
530	Alirocumab after acute coronary syndrome in patients with a history of heart failure. <i>European Heart Journal</i> , 2022, 43, 1554-1565.	1.0	23
531	Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). <i>BMC Public Health</i> , 2010, 10, 382.	1.2	22
532	Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2010, 160, 855-861.	1.2	22
533	An evidence-based score to detect prevalent peripheral artery disease (PAD). <i>Vascular Medicine</i> , 2012, 17, 342-351.	0.8	22
534	Prognostic significance of presenting blood pressure in non-ST-segment elevation acute coronary syndrome in relation to prior history of hypertension. <i>American Heart Journal</i> , 2013, 166, 716-722.	1.2	22
535	Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting. <i>JAMA Cardiology</i> , 2017, 2, 478.	3.0	22
536	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. <i>International Journal of Cardiology</i> , 2017, 245, 271-276.	0.8	22
537	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 53-65.	1.1	22
538	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>European Heart Journal</i> , 2018, 39, e1-e33.	1.0	22
539	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018, 137, 684-692.	1.6	22
540	Causes and Risk Factors for Death in Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1837-1840.	1.2	22

#	ARTICLE	IF	CITATIONS
541	Vascular spasm complicates continuous wave but not pulsed laser irradiation. <i>American Heart Journal</i> , 1989, 118, 934-941.	1.2	21
542	The Effect of Diabetes on B-Type Natriuretic Peptide Concentrations in Patients With Acute Dyspnea: An analysis from the Breathing Not Properly Multinational Study. <i>Diabetes Care</i> , 2004, 27, 2398-2404.	4.3	21
543	Can an elderly woman's heart be too strong?. <i>American Heart Journal</i> , 2010, 160, 849-854.	1.2	21
544	Outcomes from patients with multi-vessel disease following primary PCI. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 617-622.	0.7	21
545	Impact of Chronic Kidney Disease on Use of Evidence-Based Therapy in Stable Coronary Artery Disease: A Prospective Analysis of 22,272 Patients. <i>PLoS ONE</i> , 2014, 9, e102335.	1.1	21
546	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. <i>Thrombosis and Haemostasis</i> , 2017, 117, 940-947.	1.8	21
547	Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. <i>European Heart Journal</i> , 2018, 39, 3855-3863.	1.0	21
548	Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 426-436.	0.8	21
549	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008226.	1.4	21
550	Carotid Atherosclerosis Evolution When Targeting a Low-Density Lipoprotein Cholesterol Concentration <70 mg/dL After an Ischemic Stroke of Atherosclerotic Origin. <i>Circulation</i> , 2020, 142, 748-757.	1.6	21
551	Impact of smoking on cardiovascular outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1460-1466.	0.8	21
552	Radial access for primary PTCA in patients with acute myocardial infarction and contraindication to or impossible femoral access. , 1996, 39, 424-426.		20
553	Conservative management of patients with acute myocardial infarction and spontaneous acute patency of the infarct-related artery. <i>American Heart Journal</i> , 1997, 134, 248-252.	1.2	20
554	Long-term clinical outcomes after rescue angioplasty are not different from those of successful thrombolysis for acute myocardial infarction. <i>European Heart Journal</i> , 2005, 26, 1831-1837.	1.0	20
555	Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. <i>American Heart Journal</i> , 2012, 164, 817-824.e13.	1.2	20
556	Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2013, 166, 290-297.	1.2	20
557	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2015, 190, 34-39.	0.8	20
558	Impact of Arterial Access Site on Outcomes After Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002049.	1.4	20

#	ARTICLE	IF	CITATIONS
559	A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. <i>American Heart Journal</i> , 2016, 181, 92-100.	1.2	20
560	Compared Outcomes of ST-Segmentâ€Elevation Myocardial Infarction Patients With Multivessel Disease Treated With Primary Percutaneous Coronary Intervention and Preserved Fractional Flow Reserve of Nonculprit Lesions Treated Conservatively and of Those With Low Fractional Flow Reserve Managed Invasively: Insights From the FLOWER-MI Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e011314.	1.4	20
561	Quality of reporting internal and external validity data from randomized controlled trials evaluating stents for percutaneous coronary intervention. <i>BMC Medical Research Methodology</i> , 2009, 9, 24.	1.4	19
562	Fondaparinux with Unfractionated heparin during Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): A randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with nonâ€ST-segment elevation acute coronary syndromes initially treated with fondaparinux. <i>American Heart Journal</i> , 2010, 160, 1029-1034.e1.	1.2	19
563	Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. <i>Clinical Cardiology</i> , 2012, 35, 722-729.	0.7	19
564	Demographics, Socio-Economic Characteristics, and Risk Factor Prevalence in Patients with Non-Cardioembolic Ischaemic Stroke in Low- and Middle-Income Countries: The OPTIC Registry. <i>International Journal of Stroke</i> , 2013, 8, 4-13.	2.9	19
565	Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. <i>Circulation</i> , 2016, 134, 989-998.	1.6	19
566	Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis. <i>International Journal of Cardiology</i> , 2016, 219, 387-393.	0.8	19
567	Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 93-97.	0.4	19
568	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1638-1646.	0.7	19
569	Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007541.	1.4	19
570	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. <i>International Journal of Cardiology</i> , 2019, 286, 43-50.	0.8	19
571	A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. <i>IScience</i> , 2021, 24, 103040.	1.9	19
572	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 330-340.	5.5	19
573	Prevalence and Determinants of Subdiaphragmatic Visceral Infarction in Patients With Fatal Stroke. <i>Stroke</i> , 2007, 38, 1442-1446.	1.0	18
574	Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in nonâ€ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience. <i>American Heart Journal</i> , 2009, 158, 917-924.	1.2	18
575	Cardiovascular risk profiles and outcomes of Chinese living inside and outside China. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 668-675.	3.1	18
576	Radial versus femoral access, bleeding and ischemic events in patients with nonâ€ST-segment elevation acute coronary syndrome managed with an invasive strategy. <i>American Heart Journal</i> , 2013, 165, 583-590.e1.	1.2	18

#	ARTICLE	IF	CITATIONS
577	Documento de consenso de expertos. Tercera definición universal del infarto de miocardio. Revista Española De Cardiología, 2013, 66, 132.e1-132.e15.	0.6	18
578	Screening for coronary artery disease in asymptomatic individuals: Why and how?. Archives of Cardiovascular Diseases, 2015, 108, 675-682.	0.7	18
579	Interaction between diabetes and a high ankle-brachial index on mortality risk. European Journal of Preventive Cardiology, 2015, 22, 615-621.	0.8	18
580	Angiotensin-like 4 serum levels on admission for acute myocardial infarction are associated with no-reflow. International Journal of Cardiology, 2015, 187, 511-516.	0.8	18
581	Editor's Choice-Medically managed patients with non-ST-elevation acute myocardial infarction have heterogeneous outcomes, based on performance of angiography and extent of coronary artery disease. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 262-271.	0.4	18
582	Differences in Characteristics and Outcomes Between Asian and Non-Asian Patients in the TIA Registry. Stroke, 2017, 48, 1779-1787.	1.0	18
583	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective. JAMA Cardiology, 2017, 2, 525.	3.0	18
584	Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-specified Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2021, 10, e015560.	1.6	18
585	Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. EuroIntervention, 2020, 16, 627-633.	1.4	18
586	Left main coronary spontaneous dissection: Progressive angiographic healing without coronary surgery. American Heart Journal, 1991, 122, 1757-1759.	1.2	17
587	Cardiovascular Ischemic Event Rates in Outpatients With Symptomatic Atherothrombosis or Risk Factors in the United States. Critical Pathways in Cardiology, 2009, 8, 91-97.	0.2	17
588	Impact of diabetes mellitus and metabolic syndrome on acute and chronic on-clopidogrel platelet reactivity in patients with stable coronary artery disease undergoing drug-eluting stent placement. American Heart Journal, 2014, 168, 940-947.e5.	1.2	17
589	Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. European Journal of Preventive Cardiology, 2014, 21, 1531-1540.	0.8	17
590	Activated Clotting Time and Outcomes During Percutaneous Coronary Intervention for Non-ST-Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	17
591	Prognostic impact of non-compliance with guidelines-recommended times to reperfusion therapy in ST-elevation myocardial infarction. The FAST-MI 2010 registry. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 26-33.	0.4	17
592	Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 500-510.	0.4	17
593	The Intracranial Bleeding-LEEDS Score and the Risk of Intracranial Hemorrhage in Ischemic Stroke Patients Under Antiplatelet Treatment. Cerebrovascular Diseases, 2017, 43, 145-151.	0.8	17
594	One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction. JAMA Cardiology, 2017, 2, 791.	3.0	17

#	ARTICLE	IF	CITATIONS
595	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk of Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 645-654.	1.1	17
596	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007133.	1.4	17
597	Non-cardioembolic stroke/transient ischaemic attack in Asians and non-Asians: A post-hoc analysis of the PERFORM study. <i>European Stroke Journal</i> , 2019, 4, 65-74.	2.7	17
598	Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 4.	1.0	17
599	DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 634-646.	1.1	17
600	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021, 10, e017008.	1.6	17
601	Decreased prevalence of late potentials with mechanical versus thrombolysis-induced reperfusion in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1996, 27, 1343-1348.	1.2	16
602	How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. <i>American Heart Journal</i> , 2014, 168, 622-631.e2.	1.2	16
603	Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications. <i>Circulation</i> , 2016, 134, 571-573.	1.6	16
604	Relative efficacy and safety of ticagrelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. <i>Clinical Cardiology</i> , 2017, 40, 390-398.	0.7	16
605	Interleukin-18 in patients with acute coronary syndromes. <i>Clinical Cardiology</i> , 2019, 42, 1202-1209.	0.7	16
606	Treat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes. <i>European Stroke Journal</i> , 2019, 4, 271-280.	2.7	16
607	Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 100-111.	0.7	16
608	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e539-e546.	1.4	16
609	Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e1090-e1098.	1.4	16
610	Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2007, 98, 420-6.	1.8	16
611	Patterns of use of heparins in ACS. <i>Thrombosis and Haemostasis</i> , 2003, 90, 519-527.	1.8	15
612	Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. <i>American Heart Journal</i> , 2007, 153, 493-499.	1.2	15

#	ARTICLE	IF	CITATIONS
613	Use of Heparins in Non-ST-Elevation Acute Coronary Syndromes. <i>American Journal of Medicine</i> , 2007, 120, 63-71.	0.6	15
614	Management and outcomes following an acute coronary event in patients with chronic heart failure 1999–2007. <i>European Journal of Heart Failure</i> , 2012, 14, 464-472.	2.9	15
615	Screening for abdominal aortic aneurysm in coronary care unit patients with acute myocardial infarction using portable transthoracic echocardiography. <i>European Heart Journal Cardiovascular Imaging</i> , 2012, 13, 574-578.	0.5	15
616	Atherothrombotic Disease, Traditional Risk Factors, and 4-Year Mortality in a Latin American Population: The REACH Registry. <i>Clinical Cardiology</i> , 2012, 35, 451-457.	0.7	15
617	Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibrillation in a large contemporary international survey: insights from RealiseAF. <i>Europace</i> , 2013, 15, 1733-1740.	0.7	15
618	Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. <i>PLoS ONE</i> , 2015, 10, e0125164.	1.1	15
619	Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. <i>American Heart Journal</i> , 2016, 182, 111-118.	1.2	15
620	Factors Associated With Infarct-Related Artery Patency Before Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the FAST-MI 2010 Registry). <i>American Journal of Cardiology</i> , 2016, 117, 17-21.	0.7	15
621	Quality of Life With Ivabradine in Patients With Angina Pectoris. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 31-38.	0.9	15
622	Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials. <i>American Heart Journal</i> , 2017, 194, 73-82.	1.2	15
623	THEMIS and THEMIS-PCI. <i>European Heart Journal</i> , 2019, 40, 3378-3381.	1.0	15
624	Impact of Bleeding and Myocardial Infarction on Mortality in All-Coroner Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009177.	1.4	15
625	Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008349.	1.4	15
626	Five-Year Prognosis After TIA or Minor Ischemic Stroke in Asian and Non-Asian Populations. <i>Neurology</i> , 2021, 96, e54-e66.	1.5	15
627	Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial. <i>American Heart Journal</i> , 2022, 248, 72-83.	1.2	15
628	One-Year Major Cardiovascular Events After Restrictive Versus Liberal Blood Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Trial. <i>Circulation</i> , 2022, 145, 486-488.	1.6	15
629	Incidence, consequences, and risk factors of early reocclusion after primary and/or rescue percutaneous transluminal coronary angioplasty for acute myocardial infarction. <i>American Journal of Cardiology</i> , 1998, 82, 554-558.	0.7	14
630	Predictors of Annual Pharmaceutical Costs in Australia for Community-Based Individuals with, or at Risk of, Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 85-94.	1.0	14

#	ARTICLE	IF	CITATIONS
631	Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 659-665.	0.4	14
632	Emergency Coronary Angiography After Out-of-Hospital Cardiac Arrest. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006804.	1.4	14
633	Pre-treatment with a P2Y12 antagonist before PCI in STEMI: why should we wait?. <i>European Heart Journal</i> , 2019, 40, 1211-1213.	1.0	14
634	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 179.	2.7	14
635	Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1087-1095.	1.8	14
636	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1125-1139.	1.5	14
637	Intracranial Hemorrhage in the TST Trial. <i>Stroke</i> , 2022, 53, 457-462.	1.0	14
638	Failure of angiography to diagnose thermal perforation complicating laser angioplasty in a rabbit. <i>American Journal of Cardiology</i> , 1987, 60, 751-752.	0.7	13
639	Impact of Carotid Endarterectomy on Medical Secondary Prevention After a Stroke or a Transient Ischemic Attack. <i>Stroke</i> , 2006, 37, 2880-2885.	1.0	13
640	Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery disease. <i>Journal of Internal Medicine</i> , 2010, 267, 621-633.	2.7	13
641	Recurrent ischemia across the spectrum of acute coronary syndromes: Prevalence and prognostic significance of (Re-)infarction and ST-segment changes in a large contemporary registry. <i>International Journal of Cardiology</i> , 2010, 145, 15-20.	0.8	13
642	Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis. <i>Medical Journal of Australia</i> , 2012, 196, 193-197.	0.8	13
643	Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): An international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percutaneous coronary intervention. <i>American Heart Journal</i> . 2013, 166, 960-967.e6.	1.2	13
644	Beta-Blockers in Asymptomatic Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 253-255.	1.2	13
645	Complexity of atrial fibrillation patients and management in Chinese ethnicity in routine daily practice: Insights from the RealiseAF Taiwanese cohort. <i>Journal of Cardiology</i> , 2014, 64, 211-217.	0.8	13
646	Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003272.	1.4	13
647	Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. <i>Heart</i> , 2016, 102, 1396-1402.	1.2	13
648	Clinical outcomes in patients with stable coronary artery disease with vs. without a history of myocardial revascularization. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 2, 23-32.	1.8	13

#	ARTICLE	IF	CITATIONS
649	Symptomatic Patients Remain at Substantial Risk of Arterial Disease Complications Before and After Endarterectomy or Stenting. <i>Stroke</i> , 2017, 48, 1005-1010.	1.0	13
650	Long-Term Outcomes of Stenting the Proximal Left Anterior Descending Artery in the PROTECT Trial. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 548-556.	1.1	13
651	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E217-E225.	0.7	13
652	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005635.	1.4	13
653	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. <i>American Heart Journal</i> , 2019, 212, 13-22.	1.2	13
654	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2346-2355.	1.1	13
655	Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor). <i>Journal of the American College of Cardiology</i> , 2021, 77, 2366-2377.	1.0	13
656	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. <i>Thrombosis and Haemostasis</i> , 2020, 120, 348-362.	1.8	13
657	Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1795-1806.	0.8	13
658	Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2366-2377.	1.2	13
659	Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1000-1008.	0.7	13
660	Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. <i>Journal of the American Heart Association</i> , 2022, 11, e024999.	1.6	13
661	Effect of heparin and enoxaparin on platelet interaction with fibrin clots. <i>Thrombosis Research</i> , 1992, 65, 187-191.	0.8	12
662	The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: Results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an international randomized Evaluation (STEEPLE) trial. <i>American Heart Journal</i> , 2009, 157, 125-131.	1.2	12
663	Improving the management of non-ST elevation acute coronary syndromes: systematic evaluation of a quality improvement programme. <i>European Quality Improvement Programme for Acute Coronary Syndrome: The EQUIP-ACS project protocol and design</i> . <i>Trials</i> , 2010, 11, 5.	0.7	12
664	Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs. <i>Heart</i> , 2011, 97, 1834-1840.	1.2	12
665	A strategy for addressing aspirin hypersensitivity in patients requiring urgent PCI. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012, 1, 75-78.	0.4	12
666	Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study. <i>International Journal of Cardiology</i> , 2013, 166, 210-214.	0.8	12

#	ARTICLE	IF	CITATIONS
667	Management of outpatients in France with stable coronary artery disease. Findings from the prospective observational Longitudinal Registry of patients with stable coronary artery disease (CLARIFY) registry. Archives of Cardiovascular Diseases, 2014, 107, 452-461.	0.7	12
668	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. Circulation: Cardiovascular Interventions, 2016, 9, e002995.	1.4	12
669	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	12
670	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. European Journal of Preventive Cardiology, 2018, 25, 377-387.	0.8	12
671	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. JACC: Cardiovascular Interventions, 2019, 12, 983-992.	1.1	12
672	HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome. Journal of the American Heart Association, 2020, 9, e017578.	1.6	12
673	Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 153-163.	0.4	12
674	The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl. European Heart Journal, 2021, 42, 4865-4866.	1.0	12
675	A patency-oriented strategy for early management of acute myocardial infarction using emergency coronary angiography and selective coronary angioplasty. American Journal of Cardiology, 1992, 69, 1383-1388.	0.7	11
676	Usefulness of Quantitative Versus Qualitative ST-Segment Depression for Risk Stratification of Non-ST Elevation Acute Coronary Syndromes in Contemporary Clinical Practice. American Journal of Cardiology, 2008, 101, 919-924.	0.7	11
677	Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention. Trials, 2009, 10, 29.	0.7	11
678	Carotid plaque and intima-media thickness and the incidence of ischemic events in patients with atherosclerotic vascular disease. Vascular Medicine, 2011, 16, 323-330.	0.8	11
679	Towards evidence-based percutaneous coronary intervention: The Rene Laennec lecture in clinical cardiology. European Heart Journal, 2012, 33, 1878-1885.	1.0	11
680	The cost implications of an early versus delayed invasive strategy in acute coronary syndromes: the TIMACS study. Journal of Medical Economics, 2014, 17, 415-422.	1.0	11
681	Impact of Living and Socioeconomic Characteristics on Cardiovascular Risk in Ischemic Stroke Patients. International Journal of Stroke, 2014, 9, 1065-1072.	2.9	11
682	Effect of Coronary Thrombus Aspiration During Primary Percutaneous Coronary Intervention on One-Year Survival (from the FAST-MI 2010 Registry). American Journal of Cardiology, 2014, 114, 1651-1657.	0.7	11
683	In-hospital management and outcomes of acute coronary syndromes in relation to prior history of heart failure. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 214-222.	0.4	11
684	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. International Journal of Cardiology, 2017, 243, 132-139.	0.8	11

#	ARTICLE	IF	CITATIONS
685	Management and clinical outcome of stable coronary artery disease in Austria. Wiener Klinische Wochenschrift, 2017, 129, 879-892.	1.0	11
686	Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). American Journal of Cardiology, 2018, 122, 944-951.	0.7	11
687	Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. Journal of Thrombosis and Thrombolysis, 2019, 48, 563-569.	1.0	11
688	Reply. Journal of the American College of Cardiology, 2019, 74, 1849-1850.	1.2	11
689	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006660.	0.9	11
690	Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. European Journal of Preventive Cardiology, 2021, 28, 432-445.	0.8	11
691	Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Network Open, 2022, 5, e2148172.	2.8	11
692	Universal reperfusion therapy can be implemented: Lessons from 20 years of management of patients admitted within 6 hours of symptom onset with ST-segment elevation acute myocardial infarction. Archives of Cardiovascular Diseases, 2009, 102, 259-267.	0.7	10
693	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome. International Journal of Cardiology, 2014, 170, e59-e62.	0.8	10
694	Death (After Percutaneous Coronary Intervention) Is No Longer What It Used to Be. Circulation, 2014, 129, 1267-1269.	1.6	10
695	Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex. American Journal of Medicine, 2015, 128, 914.e11-914.e19.	0.6	10
696	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	10
697	Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events. Clinical Cardiology, 2017, 40, 732-739.	0.7	10
698	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Tj ETQq0 0 0 rgBT /Overlock 10 2017, 120, 904-910.	0.7	10
699	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. International Journal of Cardiology, 2018, 270, 96-101.	0.8	10
700	Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007342.	1.4	10
701	Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, , .	1.4	10
702	Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006581.	0.9	10

#	ARTICLE	IF	CITATIONS
703	Residual area at risk after anterior myocardial infarction: Are ST segment changes during coronary angioplasty a reliable indicator? A comparison with technetium 99m-labeled sestamibi single-photon emission computed tomography. <i>Journal of Nuclear Cardiology</i> , 1997, 4, 11-17.	1.4	9
704	Predischarge C-Reactive Protein and 1-year Outcome After Acute Coronary Syndromes. <i>American Journal of Medicine</i> , 2006, 119, 684-692.	0.6	9
705	Timing of events in STEMI patients treated with immediate PCI or standard medical therapy: Implications on optimisation of timing of treatment from the CARESS-in-AMI trial. <i>International Journal of Cardiology</i> , 2012, 154, 275-281.	0.8	9
706	The Association Between Prior Use of Aspirin and/or Warfarin and the In-hospital Management and Outcomes in Patients Presenting With Acute Coronary Syndromes: Insights From the Global Registry of Acute Coronary Events (GRACE). <i>Canadian Journal of Cardiology</i> , 2012, 28, 48-53.	0.8	9
707	Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 246-255.	0.4	9
708	Clinical Characteristics, Management, and Control of Permanent vs. Nonpermanent Atrial Fibrillation: Insights from the RealiseAF Survey. <i>PLoS ONE</i> , 2014, 9, e86443.	1.1	9
709	Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke. <i>Stroke</i> , 2016, 47, 1045-1052.	1.0	9
710	Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	9
711	Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1093-1100.	1.8	9
712	Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005308.	1.4	9
713	Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1553-1561.	1.1	9
714	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 680.	3.0	9
715	Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 400-409.	0.7	9
716	Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective <scp>CLARIFY</scp> registry. <i>European Journal of Heart Failure</i> , 2020, 22, 804-812.	2.9	9
717	Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry. <i>International Journal of Cardiology</i> , 2021, 340, 96-104.	0.8	9
718	Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial. <i>European Heart Journal</i> , 2006, 27, 1198-1206.	1.0	8
719	Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2011, 161, 878-885.	1.2	8
720	Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: Analysis of the Occluded Artery Trial (OAT). <i>American Heart Journal</i> , 2012, 163, 462-469.	1.2	8

#	ARTICLE	IF	CITATIONS
721	Comparison of Hospital Mortality During ST-Segment Elevation Myocardial Infarction in the Era of Reperfusion Therapy in Women Versus Men and in Older Versus Younger Patients. <i>American Journal of Cardiology</i> , 2013, 111, 1708-1713.	0.7	8
722	Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort. <i>Cardiovascular Therapeutics</i> , 2013, 31, 45-52.	1.1	8
723	Outcomes and Excess Costs among Patients with Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2013, 22, 724-730.	0.2	8
724	Thiazolidinedione use is not associated with worse cardiovascular outcomes: A study in 28,332 high risk patients with diabetes in routine clinical practice. <i>International Journal of Cardiology</i> , 2013, 167, 1380-1384.	0.8	8
725	Benefit of revascularization for stable ischaemic heart disease: the jury is still out. <i>European Heart Journal</i> , 2013, 34, 1534-1538.	1.0	8
726	Bivalirudin in percutaneous coronary intervention: The EUROpean BiVallrudin UtiliSatIOn in Practice (EUROVISION) Registry. <i>International Journal of Cardiology</i> , 2014, 173, 290-294.	0.8	8
727	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. <i>International Journal of Cardiology</i> , 2016, 218, 291-297.	0.8	8
728	Presentation, management and outcome of heparin-induced thrombocytopenia after valvular heart surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 1132-1138.	0.6	8
729	Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e002951.	2.1	8
730	Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trial. <i>International Journal of Cardiology</i> , 2016, 211, 119-123.	0.8	8
731	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	8
732	Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2548-2556.	1.1	8
733	Impact of acute infarct-related artery patency before percutaneous coronary intervention on 30-day outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention in the EUROMAX trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 514-521.	0.4	8
734	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Journal of the American Heart Association</i> , 2018, 7, e009260.	1.6	8
735	Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. <i>Clinical Chemistry</i> , 2019, 65, 781-790.	1.5	8
736	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2331-2341.	1.1	8
737	Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. <i>Drugs</i> , 2020, 80, 995-1005.	4.9	8
738	Restrictive vs liberal red blood cell transfusion strategies in patients with acute myocardial infarction and anemia: Rationale and design of the REALITY trial. <i>Clinical Cardiology</i> , 2021, 44, 143-150.	0.7	8

#	ARTICLE	IF	CITATIONS
739	Early behavior of biochemical markers in patients with Thrombolysis in Myocardial Infarction grade 2 flow in the infarct artery as opposed to other flow grades after intravenous thrombolysis for acute myocardial infarction. <i>American Heart Journal</i> , 1997, 134, 1044-1051.	1.2	7
740	Delphi-Consensus Weights for Ischemic and Bleeding Events to Be Included in a Composite Outcome for RCTs in Thrombosis Prevention. <i>PLoS ONE</i> , 2011, 6, e18461.	1.1	7
741	Characteristics and Evidence-Based Management of Stable Coronary Artery Disease Patients in Canada Compared With the Rest of the World: Insights From the CLARIFY Registry. <i>Canadian Journal of Cardiology</i> , 2014, 30, 132-137.	0.8	7
742	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	7
743	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 158-165.	0.4	7
744	Activated Clotting Time to Guide Heparin Dosing in Non-â€œST-Segmentâ€œ Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006084.	1.4	7
745	Ticagrelor in patients with heart failure after acute coronary syndromesâ€œ Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2019, 213, 57-65.	1.2	7
746	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004945.	0.9	7
747	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 222-230.	1.4	7
748	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 22-30.	1.4	7
749	Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUSâ€œTIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e015785.	1.6	7
750	Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-â€œST-Segmentâ€œ Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009759.	1.4	7
751	Long-term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUSâ€œTIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020446.	1.6	7
752	Atrial Fibrillation Management Strategies in Routine Clinical Practice: Insights from the International RealiseAF Survey. <i>PLoS ONE</i> , 2016, 11, e0147536.	1.1	7
753	Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT. <i>Journal of Clinical Lipidology</i> , 2022, 16, 389-402.	0.6	7
754	Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1842-1851.	0.8	7
755	Clinical Perspectives. <i>European Heart Journal</i> , 1998, 19, 1282-1293.	1.0	6
756	Plant lipids that lower serum cholesterol. <i>European Heart Journal</i> , 1999, 20, 1527-1529.	1.0	6

#	ARTICLE	IF	CITATIONS
757	Impact of smoking on the incidence and survival of cardiogenic shock complicating acute myocardial infarction treated with reperfusion therapy. <i>American Journal of Cardiology</i> , 2002, 89, 73-75.	0.7	6
758	Unmet medical needs and therapeutic opportunities in stable angina. <i>Country Review Ukraine</i> , 2005, 7, H7-H15.	0.8	6
759	A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE). <i>Archives of Cardiovascular Diseases</i> , 2008, 101, 723-735.	0.7	6
760	Prevalence of Embolic Signals in Acute Coronary Syndromes. <i>Stroke</i> , 2010, 41, 261-266.	1.0	6
761	Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry. <i>Clinical Therapeutics</i> , 2011, 33, 1456-1465.	1.1	6
762	Ticagrelor in Patients With Acute Coronary Syndromes and Stroke. <i>Stroke</i> , 2013, 44, 1477-1479.	1.0	6
763	Predictors of health care use among patients with or at high risk of atherothrombotic disease: Two-year follow-up data. <i>International Journal of Cardiology</i> , 2014, 175, 72-77.	0.8	6
764	Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: Analysis of the CLARIFY registry. <i>Medicina (Lithuania)</i> , 2015, 51, 240-246.	0.8	6
765	“Off-Hours” Versus “On-Hours” Presentation in ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2385-2387.	1.2	6
766	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	6
767	Identifying patients with acute total coronary occlusion in NSTEMACS: finding the high-risk needle in the haystack. <i>European Heart Journal</i> , 2017, 38, 3090-3093.	1.0	6
768	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. <i>International Journal of Cardiology</i> , 2018, 263, 24-28.	0.8	6
769	Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis. <i>Journal of Cardiology</i> , 2018, 71, 494-504.	0.8	6
770	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007734.	1.4	6
771	Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. <i>International Journal of Cardiology</i> , 2019, 278, 217-222.	0.8	6
772	Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 309-317.	0.4	6
773	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1369-1378.	0.7	6
774	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003006.	1.6	6

#	ARTICLE	IF	CITATIONS
775	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. <i>International Journal of Cardiology</i> , 2021, 337, 1-8.	0.8	6
776	Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT). <i>EuroIntervention</i> , 2009, 5, 610-618.	1.4	6
777	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 282-293.	1.1	6
778	Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. <i>Circulation</i> , 2022, 145, 1471-1479.	1.6	6
779	Percutaneous pulsed dye laser recanalization of experimental venous thrombosis. <i>American Heart Journal</i> , 1991, 122, 1177-1180.	1.2	5
780	Revascularization of Patients With Unstable Coronary Artery Disease. <i>American Journal of Cardiology</i> , 1997, 80, 45E-50E.	0.7	5
781	Heterogeneity of Prognosis in Patient Subsets Treated by Primary Coronary Angioplasty During Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 1998, 81, 1236-1239.	0.7	5
782	Age and lack of β -blocker therapy are associated with increased long-term mortality after primary coronary angioplasty for acute myocardial infarction. <i>International Journal of Cardiology</i> , 2003, 88, 63-68.	0.8	5
783	Does PERISCOPE Provide a New Perspective on Diabetic Treatment?. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1603.	3.8	5
784	Assessment of Atherothrombosis and Its Treatment in Mexico: First Year Data of the REACH Registry. <i>Clinical Cardiology</i> , 2010, 33, 445-451.	0.7	5
785	In Germany Diabetic Patients with Coronary Artery Disease are Treated More Intensively than Diabetic Patients with Other Manifestations of Atherothrombosis – Results from the REACH Registry. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2010, 118, 51-56.	0.6	5
786	Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 280-291.	0.4	5
787	Treating coronary artery disease in patients with a history of cerebrovascular disease. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 606-611.	0.7	5
788	Follow the Data. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 225-227.	1.1	5
789	Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 3, pww018.	1.4	5
790	ST-segment resolution with bivalirudin versus heparin and routine glycoprotein IIb/IIIa inhibitors started in the ambulance in ST-segment elevation myocardial infarction patients transported for primary percutaneous coronary intervention: The EUROMAX ST-segment resolution substudy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 404-411.	0.4	5
791	Duration of antiplatelet therapy after DES implantation: can we trust non-inferiority open-label trials?. <i>European Heart Journal</i> , 2017, 38, 1044-1047.	1.0	5
792	Cangrelor compared with clopidogrel in patients with prior myocardial infarction – Insights from the CHAMPION trials. <i>International Journal of Cardiology</i> , 2018, 250, 49-55.	0.8	5

#	ARTICLE	IF	CITATIONS
793	Evaluation of Apixaban in stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study. <i>Clinical Cardiology</i> , 2019, 42, 851-859.	0.7	5
794	The DAPT Score in Sweden. <i>Journal of the American College of Cardiology</i> , 2019, 73, 113-114.	1.2	5
795	No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1012-1014.	1.1	5
796	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E516-E526.	0.7	5
797	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. <i>American Heart Journal</i> , 2020, 225, 97-107.	1.2	5
798	Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 187-196.	0.7	5
799	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 768-780.	1.1	5
800	Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 93-104.	1.0	5
801	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction – findings from the LATITUDE-TIMI 60 trial. <i>American Heart Journal</i> , 2022, 243, 147-157.	1.2	5
802	Prevalence and treatment of cardiovascular risk factors in outpatients with atherothrombosis in the Middle East. <i>Heart Asia</i> , 2011, 3, 77-81.	1.1	5
803	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.	1.4	5
804	WEST: new data on the integration of early thrombolysis and mechanical intervention in the early management of STEMI. <i>European Heart Journal</i> , 2006, 27, 1511-1512.	1.0	4
805	The evolving nature of coronary artery disease. <i>European Heart Journal Supplements</i> , 2011, 13, C14-C18.	0.0	4
806	Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value. <i>Thrombosis and Haemostasis</i> , 2014, 112, 12-14.	1.8	4
807	No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial. <i>International Journal of Cardiology</i> , 2014, 176, 300-302.	0.8	4
808	Patient education after acute myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 761-767.	0.6	4
809	Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysis. <i>International Journal of Cardiology</i> , 2017, 243, 95-97.	0.8	4
810	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet) Trial. <i>Journal of the American College of Cardiology</i> , 2012, 60, 112-117.	1.2	4

#	ARTICLE	IF	CITATIONS
811	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. <i>Clinical Cardiology</i> , 2019, 42, 797-805.	0.7	4
812	Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual) <i>Tj ETQq0 0 0 rgBT, /Overlock 10 Tf 50</i>	0.7	4
813	Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. <i>International Journal of Cardiology</i> , 2020, 320, 27-34.	0.8	4
814	Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial. <i>Canadian Journal of Cardiology</i> , 2021, 37, 122-130.	0.8	4
815	Regional variation in patients and outcomes in the GLOBAL LEADERS trial. <i>International Journal of Cardiology</i> , 2021, 324, 30-37.	0.8	4
816	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2772-2780.	1.9	4
817	Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 349-356.	0.7	4
818	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120010390.	1.4	4
819	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-eluting Stent Implantation: Per-protocol Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024291.	1.6	4
820	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120009495.	1.4	4
821	Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 777-785.	1.4	4
822	Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1542-1549.	0.8	4
823	Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analyses. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2023, 9, 194-202.	1.8	4
824	B-Type Natriuretic Peptide Levels in Patients in the Emergency Department With Possible Heart Failure and Previous Stable Angina Pectoris and/or Healed Myocardial Infarction. <i>American Journal of Cardiology</i> , 2005, 96, 1370-1373.	0.7	3
825	Pharmacologic management of stable angina: role of ivabradine. <i>Country Review Ukraine</i> , 2006, 8, D16-D23.	0.8	3
826	Major bleeding after PCI. Where is our crystal ball?. <i>European Heart Journal</i> , 2007, 28, 1917-1919.	1.0	3
827	Measurement and prevention of myocardial injury during percutaneous coronary intervention. <i>Heart</i> , 2007, 93, 656-657.	1.2	3
828	A Meta-Analysis That Misses the Mark. <i>Journal of the American College of Cardiology</i> , 2008, 52, 578-580.	1.2	3

#	ARTICLE	IF	CITATIONS
829	Devices to protect against embolization during primary angioplasty for ST-segment elevation myocardial infarction: the good, the bad and the ugly. <i>European Heart Journal</i> , 2008, 29, 2953-2954.	1.0	3
830	Response to Letter Regarding Article, "Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk". <i>Circulation</i> , 2009, 119, .	1.6	3
831	Impact of Systemic Hypertension on the Diagnostic Performance of B-Type Natriuretic Peptide in Patients With Acute Dyspnea. <i>American Journal of Cardiology</i> , 2009, 104, 966-971.	0.7	3
832	Economic implications of obesity among people with atherothrombotic disease. <i>International Journal of Obesity</i> , 2010, 34, 1284-1292.	1.6	3
833	Letter by Mehran et al Regarding Article, "Bleeding Academic Research Consortium Consensus Report: The Food and Drug Administration Perspective". <i>Circulation</i> , 2012, 125, e460.	1.6	3
834	Does lay media ranking of hospitals reflect lower mortality in treating acute myocardial infarction?. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 489-498.	0.7	3
835	The Impact of Lost Therapeutic Benefit (<sc>LTB</sc>) in High-Risk Hypertensive Patients: 2-Year Follow-Up Data from the Australian <sc>REACH</sc> Registry. <i>Cardiovascular Therapeutics</i> , 2013, 31, 370-376.	1.1	3
836	Insufficient control of heart rate in stable coronary artery disease patients in Latvia. <i>Medicina (Lithuania)</i> , 2014, 50, 295-302.	0.8	3
837	Impact of participation in randomized trials of reperfusion therapy on the time to reperfusion and hospital mortality in ST-segment elevation myocardial infarction: A single-centre cohort study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 193-197.	0.4	3
838	Early clinical outcomes as a function of use of newer oral P2Y ₁₂ inhibitors versus clopidogrel in the EUROMAX trial. <i>Open Heart</i> , 2017, 4, e000677.	0.9	3
839	Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 736-745.	0.4	3
840	Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Tj ETQq0 0 0 rgBT Overlock 10 Tf 50 2		
841	Simple risk models to predict cardiovascular death in patients with stable coronary artery disease. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 287-294.	1.8	3
842	Prevalence, Incidence and Prognostic Implications of Left Bundle Branch Block in Patients with Chronic Coronary Syndromes (From the CLARIFY Registry). <i>American Journal of Cardiology</i> , 2021, 150, 40-46.	0.7	3
843	A simple nomogram for early prediction of myocardial reperfusion after pre-hospital thrombolysis. <i>EuroIntervention</i> , 2011, 7, 248-255.	1.4	3
844	Specificities of Ischemic Stroke Risk Factors in Arab-Speaking Countries. <i>Cerebrovascular Diseases</i> , 2017, 43, 169-177.	0.8	3
845	Atrial Fibrillation Screening: The Tools Are Ready, But Should We Do It?. <i>Circulation</i> , 2022, 145, 955-958.	1.6	3
846	Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, 101161CIRCGEN121003503.	1.6	3

#	ARTICLE	IF	CITATIONS
847	Coronary Angiographic Features and Major Adverse Cardiac or Cerebrovascular Events in People Living With Human Immunodeficiency Virus Presenting With Acute Coronary Syndrome. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, 101161CIRCINTERVENTIONS122011945.	1.4	3
848	Correspondence. <i>Journal of the American College of Cardiology</i> , 1999, 33, 288.	1.2	2
849	A tale of two countries: costs and financial incentives for provisional stenting during percutaneous coronary intervention in France and the United States. <i>European Journal of Health Economics</i> , 2002, 3, 235-239.	1.4	2
850	Enoxaparin in non-ST segment elevation acute coronary syndromes: duration of therapy is essential to benefit. <i>European Heart Journal</i> , 2004, 25, 1667-1669.	1.0	2
851	Atherothrombosis and Stroke – A Lot More to Know!. <i>Cerebrovascular Diseases</i> , 2005, 20, 139-140.	0.8	2
852	Recurrent acute coronary syndromes are associated with increased shear induced platelet aggregation. A case–control study. <i>International Journal of Cardiology</i> , 2012, 155, 313-314.	0.8	2
853	Response to Letter Regarding Article, “Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial”. <i>Circulation</i> , 2014, 129, e494-5.	1.6	2
854	Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 174, 90-95.	0.8	2
855	The year in cardiology 2015: coronary intervention. <i>European Heart Journal</i> , 2016, 37, ehv708.	1.0	2
856	Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 214-220.	1.4	2
857	Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. <i>American Heart Journal</i> , 2017, 188, 147-155.	1.2	2
858	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1704-1711.	1.8	2
859	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. <i>Canadian Journal of Cardiology</i> , 2020, 36, 747-755.	0.8	2
860	Use of risk scores to identify lower and higher risk subsets among COMPASS-eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry. <i>Clinical Cardiology</i> , 2021, 44, 58-65.	0.7	2
861	The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 28-33.	1.8	2
862	The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL) Tj ETQq0 0 0 rgBT /Overlock 10 T <i>Cardiology</i> , 2021, 44, 1002-1010.	0.7	2
863	Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 398-407.	0.4	2
864	Direct-acting Anticoagulants in Chronic Coronary Syndromes. <i>European Cardiology Review</i> , 2020, 15, 1-7.	0.7	2

#	ARTICLE	IF	CITATIONS
865	Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction. <i>World Journal of Cardiology</i> , 2010, 2, 13.	0.5	2
866	Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus non-cardiologists: the international prospective CLARIFY registry. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 107-114.	0.3	2
867	Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, , CIRCINTERVENTIONS120011035.	1.4	2
868	Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 336-349.	0.4	2
869	Feasibility and safety of pulsed dye laser irradiation in the pulmonary arteries. <i>American Heart Journal</i> , 1993, 126, 1477-1480.	1.2	1
870	Primary PTCA: Possibly the Best, Often the Only Choice for Reperfusion in Acute Myocardial Infarction. , 1997, 4, 331-336.		1
871	Overview of large morbidity/mortality trials with ivabradine: focus on the BEAUTiFUL study. <i>Country Review Ukraine</i> , 2007, 9, F15-F19.	0.8	1
872	Prior Cardiovascular Interventions Are Not Associated With Worsened Clinical Outcomes in Patients With Symptomatic Atherothrombosis. <i>Critical Pathways in Cardiology</i> , 2010, 9, 116-125.	0.2	1
873	Statins in the elderly: What evidence of their benefit in prevention?. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 61-65.	0.7	1
874	Response to Letter by Calvet et al Regarding Article, "Prevalence of Coronary Atherosclerosis in Patients With Cerebral Infarction". <i>Stroke</i> , 2011, 42, .	1.0	1
875	Reply to Letter Regarding Article, "The Impact of Collateral Flow to the Occluded Infarct-Related Artery on Clinical Outcomes in Patients With Recent Myocardial Infarction: A Report From the Randomized Occluded Artery Trial". <i>Circulation</i> , 2011, 123, .	1.6	1
876	Response to Letter Regarding Article, "Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO". <i>Circulation</i> , 2012, 126, .	1.6	1
877	Response to Letter Regarding Article, "Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation". <i>Circulation</i> , 2014, 129, e21-2.	1.6	1
878	Frequency of the Use of Low- Versus High-Dose Aspirin in Dual Antiplatelet Therapy After Percutaneous Coronary Intervention (from the Dual Antiplatelet Therapy Study). <i>American Journal of Cardiology</i> , 2014, 113, 1146-1152.	0.7	1
879	Bivalirudin versus heparin use for patients undergoing PPCI. <i>Lancet</i> , The, 2015, 385, 2043-2044.	6.3	1
880	Reply. <i>Journal of the American College of Cardiology</i> , 2018, 71, 108.	1.2	1
881	Antiplatelet and Anticoagulant Drugs. , 2018, , 303-320.		1
882	Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. <i>American Journal of Medicine</i> , 2020, 133, 1302-1312.	0.6	1

#	ARTICLE	IF	CITATIONS
883	External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E513-E522.	0.7	1
884	Myocardial Infarction and Evolocumab. <i>JAMA Cardiology</i> , 2021, 6, 1220-1221.	3.0	1
885	Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI: a post hoc analysis of the randomized GLOBAL LEADERS trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 756-773.	0.4	1
886	Individualizing dual antiplatelet therapy (DAPT) duration based on bleeding risk, ischemic risk, or both: An analysis from the DAPT Study. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.3	1
887	Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI. <i>American Heart Journal</i> , 2022, 249, 23-23.	1.2	1
888	Percutaneous coronary intervention in diabetics with prior coronary artery bypass surgery: sweet or sour?. <i>European Heart Journal</i> , 2002, 23, 1411-1412.	1.0	0
889	Circadian variations in outcome of primary percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2003, 42, 2172.	1.2	0
890	Do the benefits of early invasive therapy for non-STE acute coronary syndromes persist with long-term follow-up?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 246-247.	3.3	0
891	Revascularization Before Noncardiac Surgery: Is There an Impact of Drug-Eluting Stent Thrombosis?. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1398.	1.2	0
892	Late Intervention on an Occluded Infarct-Related Artery: A Meta-analysis of the Randomized Controlled Trials. <i>Clinical Medicine Cardiology</i> , 2007, 1, CMC.S356.	0.1	0
893	Ivabradine in heart failure: what about digoxin? Authors' reply. <i>Lancet</i> , The, 2008, 372, 2113-2114.	6.3	0
894	Response to "Atrial fibrillation and atherothrombosis: The importance of anticoagulation" by Escobar C and Barrios V. <i>American Heart Journal</i> , 2009, 157, e29.	1.2	0
895	Response to Letter Regarding Article, "Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease", <i>Circulation</i> , 2010, 122, .	1.6	0
896	ST Elevation Acute Coronary Syndromes in PLATO. <i>Circulation</i> , 2011, , 1.	1.6	0
897	Response to Letter Regarding Article, "Attained Educational Level and Incident Atherothrombotic Events in Low- and Middle-Income Compared With High-Income Countries", <i>Circulation</i> , 2011, 123, .	1.6	0
898	Systematic re-evaluation of the diagnosis and treatment of coronary artery disease in hospitalized elderly: Impact on medication underuse. The multicenter IRIDIA study. <i>European Geriatric Medicine</i> , 2012, 3, 219-224.	1.2	0
899	β-Blocker Use for Patients With or at Risk for Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 438.	3.8	0
900	Response to Letter Regarding Article, "Ticagrelor in Patients With Acute Coronary Syndromes and Stroke: Interpretation of Subgroups in Clinical Trials". <i>Stroke</i> , 2013, 44, e95-e96.	1.0	0

#	ARTICLE	IF	CITATIONS
901	Lack of Negative Interaction Between Use of Beta-Blockers and Statins on Cardiovascular Outcomes Among Patients With or At Risk for Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2014, 64, 845-847.	1.2	0
902	Duration of dual antiplatelet therapy after drug-eluting stent implantation. <i>Sang Thrombose Vaisseaux</i> , 2015, 27, 3-5.	0.1	0
903	Reply. <i>Journal of the American College of Cardiology</i> , 2016, 68, 669.	1.2	0
904	Reply. <i>Journal of the American College of Cardiology</i> , 2016, 68, 132-133.	1.2	0
905	Blood pressure and cardiovascular outcomes: a closer look – Authors' reply. <i>Lancet, The</i> , 2017, 389, 1296-1297.	6.3	0
906	Unreliable Observations from a Confounded Analysis of a Skewed Database. <i>American Journal of Medicine</i> , 2017, 130, e355-e356.	0.6	0
907	The Reply. <i>American Journal of Medicine</i> , 2018, 131, e129.	0.6	0
908	The Reply. <i>American Journal of Medicine</i> , 2019, 132, e622.	0.6	0
909	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y ₁₂ Inhibitor Pretreatment. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007445.	1.4	0
910	Differential effect of ticagrelor on irreversible harms in diabetes – Authors' reply. <i>Lancet, The</i> , 2020, 396, 93-94.	6.3	0
911	Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial. <i>American Heart Journal</i> , 2020, 223, 84-86.	1.2	0
912	Impact of Lower Versus Higher LDL Cholesterol Targets on Cardiovascular Events After Ischemic Stroke in Patients With Diabetes. <i>Diabetes</i> , 2021, 70, 1807-1815.	0.3	0
913	Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention – Insights from the CHAMPION program. <i>American Heart Journal Plus</i> , 2021, 9, 100043.	0.3	0
914	Stent selection in patients on oral anticoagulants: can we prevent restenosis and avoid bleeding?. <i>EuroIntervention</i> , 2009, 5, 405-407.	1.4	0
915	Results from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. , 2011, , 21-25.		0
916	Cardiovascular risk of chronic coronary syndrome patients according to vascular phenotype, diabetes, and smoking. <i>European Journal of Preventive Cardiology</i> , 2020, , .	0.8	0
917	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011069.	1.4	0
918	Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. <i>American Journal of Medicine</i> , 2022, , .	0.6	0